Elucidating the Immunoactivity of a Goat Serum Peptide by Parker, Todd Avery
Mississippi State University 
Scholars Junction 
Theses and Dissertations Theses and Dissertations 
5-11-2002 
Elucidating the Immunoactivity of a Goat Serum Peptide 
Todd Avery Parker 
Follow this and additional works at: https://scholarsjunction.msstate.edu/td 
Recommended Citation 
Parker, Todd Avery, "Elucidating the Immunoactivity of a Goat Serum Peptide" (2002). Theses and 
Dissertations. 1859. 
https://scholarsjunction.msstate.edu/td/1859 
This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at 
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of 
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com. 
ELUCIDATING THE IMMUNOACTIVITY OF A GOAT SERUM PEPTIDE 
By 
Todd Avery Parker 
A Dissertation 
Submitted to the Faculty of 
Mississippi State University 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
in Molecular Biology 
in the Department of Biochemistry and Molecular Biology 
Mississippi State, Mississippi 
May 2002 
                                                                                                                       
                                                                                                                       
                                                                                                                         
 
                                                                          
ELUCIDATING THE IMMUNOACTIVITY OF A GOAT SERUM PEPTIDE 
By 
Todd Avery Parker 
Approved: 
Kenneth O. Willeford 
Associate Professor of Biochemistry 
and Molecular  Biology 
(Director of Dissertation) 
Marvin L. Salin 
Professor of Biochemistry 
and Molecular Biology 
(Member of Committee) 
John A. Boyle 
Professor of Biochemistry 
and Molecular Biology 
(Member of Committee) 
E. David Peebles 
Professor of Poultry Science 
(Member of Committee) 
James R. Heitz 
Professor of Biochemistry 
and Molecular Biology 
(Member of Committee) 
Vance Watson 
Dean of the College of 
Agriculture and Life Sciences 
Phillip E. Ryals 
Associate Professor of Biochemistry 
and Molecular Biology 
(Graduate Coordinator) 
N a m e: T o d d A v er y P ar k er 
D at e of D e gr e e: M a y 1 1, 2 0 0 2 
I n stit uti o n:  Mi s si s si p pi St at e U ni v er sit y 
M aj or Fi el d:  M ol e c ul ar Bi ol o g y 
M aj or Pr of ess or:  Dr. Ke n n et h O. Will ef or d 
Titl e of St u d y:  E L U CI D A TI N G T H E I M M U N O A C TI VI T Y O F A G O A T S E R U M
 P E P TI D E 
P a g es i n St u d y: 9 7 
C a n di d at e f or D e gr e e of D o ct or of M ol e c ul ar Bi ol o g y 
T h e p ur p o se of t h e s e st u di e s w a s t o d et er mi n e if a n i m m u n o m o d ul at or wa s 
pr e s e nt i n c a pri n e s er u m.  C o ntr oll e d st u die s d e m o n str at e d t h at C S F-I, m at eri al 
fr a cti o n at e d fr o m c a pri n e s er u m p oss ess e d a n i m m u n o m o d ul at or y c o m p o u n d. C a pri n e 
s er u m w as f urt h er fr a cti o n at e d i nt o it s p e pti di c c o m p o n e nts a n d a s m all c o nt a mi n a nt of 
i m m u n o gl o b uli n G a n d al b u mi n ( C a pri n e s er u m fr a cti o n - i m m u n o m o d ul at or 2, or 
C S F-I 2).  T hi s w a s r efi n e d t o a t hr e e p e pti di c i s ol at e c oll e cti v el y i d e ntifi e d a s tri- pe pti di c 
i m m u n o sti m ul a nt or T PI.  C S F-I 2 d o e s n ot p o s s e s s a nti b a cteri al c a p a biliti e s ( a s t y pi c all y 
c h ar a ct eri sti c of a c ati o ni c p e pti d e or d ef e n si n), d o e s n ot c o nt ai n a l e v el of e n d ot o xi n 
s uffi ci e nt t o pr o m ote a p yr o g e ni c r e s p o n s e, a n d it s f u n cti o n al a bilit y t o i m pr o ve a ni m al 
s ur vi v al aft er a n i nf e cti o u s c h all e n ge d o e s n ot r e si d e wit h m ol e c ul ar w ei g ht c o m p o n e nt s 
gr e at er t h a n 1 0 kil o d alt o ns, eff e cti v el y e x cl u di n g t h e i m m u n o gl o bi ns, al b u mi n, 
c yt o ki n es, a n d c oll e cti ns. 
CSF-I2 was able to significantly reduce the mortality observed in chickens (from 
80% to 13%) infected with Pasteurella multocida (Willeford et al., 2000), in mice (from 
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9.8%) diagnosed with parvovirus. CSF-I2 may well prove to provide prophylactic and 
therapeutic health benefits to humans.  CSF-I2 may effectively combat pathogenesis 
when used as either an adjunct with conventional therapy (e.g., antibiotics) or when 
provided as the primary medicant. 
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The penicillin era was born in 1924 after a chance discovery by Alexander 
Fleming.  Antibiotics quickly filled a void in medical science and are recognized to have 
saved countless lives.  Man s dependence on antibiotics and the ability of bacteria to 
develop and disseminate antibiotic resistance through extra-chromosomal DNA may 
have now ushered in the end of the penicillin era. As a consequence, once-standard 
treatments for infections have become less reliable.  The efficacy of last resort 
therapies like vancomycin can no longer be taken for granted (Roberts, 2001).  Bacterial 
resistance has been reported even for recently implemented next generation antibiotics, 
such as the first oxazolidinone Linezolid (Tsiodras et al., 2001).
 The widespread prophylactic and therapeutic use of drugs has placed pathogenic 
microbes under constant antibiotic exposure, thus accelerating their need to adapt by 
generating resistance (Hancock, 1997; Aarestrup et al., 1999; Virk and Steckelburg, 
2000). The consequence of our cavalier attitude towards antibiotics may be grim.  It has 
been predicted that within one or two generations, hospital wards will return to the 
overcrowded state that existed in the early 1900's when flu epidemics killed thousands. 





li mit t h e a m o u nt of h u m a n e x p os ur e t o a nti bi oti c r e si d u e f o u n d i n f o o d pr o d u ct s ( K o g ut, 
2 0 0 0) h o w e v er ma y b e t o o littl e t o o lat e.  B a ct eri a u nr e s p o nsi v e t o a v ail a ble a nti bi oti c 
t h er a p y ar e b e c o mi n g m or e c o m m o n.  I n n o v ati o n h as b e c o m e a cl ari o n c all f or 
d e v el o pi n g n e w t h er a p e uti c r e gi m es. 
Si n c e m o st li vi n g or g a ni s m s ar e ver y si mil ar at t h e m ol e c ul ar l e v el, it i s diffi c ult 
t o fi n d s u bst a n c es t h at ar e l et h al t o c ert ai n or g a nis ms wit h o ut b ei n g h ar mf ul t o ot h ers. 
F or t hi s r e a s o n, t h er e i s a gr o wi n g i nt er e st i n di s c o v eri n g a ge nt s t h at a u g m e nt o n e s 
i n n at e i m m u n e d ef e ns es i n or d er t o pr e v e nt a n d tr e at i nf e cti o us dis e as es ( R us h, 2 0 0 1). 
I n n at e i m m u nit y is m e di at e d b y c ells, s u c h as p h a g o c yt es a n d n at ur al kill e r c ells, 
cir c ul ati n g pr ot ei ns ( e. g., t h e c o m pl e m e nt s yst e m), a n d n u m er o u s a nti mi cr o bi al p e pti d es, 
w hi c h pr o vi d e e arl y h o st d ef e ns e a g ai n st i nf e cti o n s b ef or e t h e de v el o p m e nt of a n 
a d a pti v e i m m u n e r e s p o n s e.  I n n at e i m m u nit y al s o sti m ul at e s a d a pti v e i m m u n e r e s p o n s e s 
( A b b as a n d J a n e w a y, 2 0 0 0). 
A nti mi cr o bi al p e pti de s ar e oft e n a s s o ci at e d wit h a cl a s s of p e pti d e s i d e ntifi e d as 
c ati o ni c. C ati o ni c p e pti d es ar e l et h al t o a wi d e r a n g e of mi cr o or g a nis ms, i n cl u di n g 
gr a m- p o siti v e a n d gr a m- n e g ati ve b a ct eri a, f u n gi, p ara sit e s, a n d e n v el o pe d vir u se s 
b e c a us e t h e y i n d u c e l e a k a g e i n m e m br a n es ( G a n z, 1 9 9 9).  C ati o ni c p e pti d es c a n b e 
d efi n e d a s pr ot ei n s wit h l e s s t h a n 1 0 0 a mi n o a ci d s ( m or e t y pic all y l e ss t h a n 3 5) a n d a n et 
p o siti ve c h ar g e of at l e a st + 2 (a n d u s u all y m or e t h a n + 4) b y virt u e of t heir h a vi n g a n 
e x c ess of l ysi n e a n d ar gi ni n e r esi d u es o v er a ci di c r esi d u es ( H a n c o c k, 1 9 9 7; H a n c o c k, 
1 9 9 9).  T w o s h ort c o mi n gs of t h es e n a t ur al c o m p o u n d s, h o w e v er, ar e t h at ( 1) v er y hi g h 
p e pti d e c o n c e ntr ati o n s ar e n e e de d f or a nti mi cr o bi al effi c a c y a n d ( 2) t h e diff er e n c e i n 
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toxicity (therapeutic index) between target and host cells is not sufficiently high (Maloy 
and Kari, 1995). 
The primary goal of researching immunostimulation is to minimize reliance on 
antimicrobial drugs and associated issues of resistance and residue (Rush, 2001). 
Immunostimulant preparations produce nonantigen-specific enhancement of humoral and 
cell-mediated defense mechanisms (Tizard, 1993). It is believed that, through the use of 
immune regulating or immune modulating molecules, a state of general hyperactivity of 
the immune system can be induced which may be useful in combating and/or preventing 
a microbial infection. If such a non-specific immune response could be initiated at will, 
it could be utilized to either act alone or in conjunction with a conventional treatment 
directed towards the etiological agents. This could markedly impact both the 
agricultural, veterinary, and human medical communities. 
Immunomodulators can be divided into three main groups: (a) immuno-
suppressive agents; (b) immunostimulating agents (e.g., bacillus Calmette-Guérin 
vaccine); and (c) the remaining immunomodulators, which include biological response 
modifiers (e.g., colony stimulating factors, interleukins, interferons, and tumor necrosis 
factors) (Takx-Kohlen, 1992; Molloy et al., 1993). Cytokines are soluble, low molecular 
weight polypeptides and glycopepetides produced by a broad range of cell types that have 
suppressive or enhancing effects on cellular proliferation, differentiation, activation, and 
motility. For the most part, they are not constitutively secreted, but are produced in 
response to stimulation by infectious agents or their derived products (e.g., endotoxin), 
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inflammatory mediators, mechanical injuries, and cytokines themselves (Kogut, 2000). 
An overview of some of the typical immunomodulatory agents is presented in Table 1.1. 
The concept of immunostimulation originated in 1907, when William B. Coley 
noted spontaneous tumor regression in some patients after an episode of septicemia 
(Rush and Flaminio, 2000). In human and veterinary medicine, immunostimulant 
preparations are used primarily for treatment of chronic viral or bacterial infections.  In 
some instances, immunostimulants have demonstrated efficacy as primary or adjunct 
treatment of neoplastic conditions (Rush, 2001). The proposed mechanism of action of 
nonspecific immunostimulant preparations is macrophage activation and subsequent 
release of cytokines that enhance the immune response (Rush and Flaminio, 2000). 
Prophylactic administration of immunostimulant preparations prior to pathogen exposure 
can decrease morbidity and mortality associated with acute infection (Rush, 2001). 
In human medicine, immunomodulatory preparations have progressed from crude 
microbial, viral, plant, and thymic extracts to synthetic viral complexes and chemically 
defined drugs (recombinant cytokines).  The crude extract preparations induce 
nonspecific immunomodulatory activity via macrophage activation. The benchmark of 
nonspecific immunomodulators is protection against a 50% lethal bacterial challenge in 
laboratory animals.  The more sophisticated polyribonucleotide complexes are intended 
to mimic the interferon-inducing capacity of viruses.  Newer generations of recombinant 
cytokines have selective effects on particular components of the immune system (Rush, 
2001). 
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Because cells of the immune system and naturally occurring immunomodulators 
circulate through the blood and lymphatic system, serum is a logical place to look for 
immunomodulators.  To date, only about half of the over 100 serum proteins have been 
isolated and characterized (de Gruyter, 1997), thus leaving ample opportunity for such a 
discovery.  Caprine Serum Fraction - Immunomodulator (CSF-I) is a nonadjuvanted 
immunomodulator derived from goat serum.  CSF-I remains ill-defined but is composed 
of a mixture of serum proteins and peptides.  Field trials have shown efficacy of CSF-I 
against equine lower respiratory disease, a mixed etiological challenge (Hamm et al., 
2001). This suggests that CSF-I may possess a general non-specific immunomodulator, 
enabling recipients to combat a variety of stress challenges.  However, no clinical trials 
had been performed. 
The purpose of these studies was to determine if an immunomodulator was 
present in caprine serum by establishing its clinical efficacy in a murine model of 
salmonellosis. Further studies were performed in order to isolate and characterize the 
active agent and to elucidate its spectrum of efficacy and mode of action. 
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Table 1.1. Classification schema for immunotherapeutic drugs, adapted from Hadden and Smith, 1992 and Hadden, 1993. 
Class Example(s) Biological Activity
Biologic agents 
Cytokines Interferons Antiviral, immunomodulatory, and antiproliferative activity 
Colony stimulating factors Induce proliferation/differentiation of granulocyte progenitor cells 
Fungal products Glucans Expand the reticuloendothelial system and activate macrophages 
Thymic hormones Thymulin, Thymopoietin Modulate T cell function 
Microbial products Propionbacterium acnes Stimulates macrophages, IL-1 and IFN production, and NK cells 
Mycobacterium Macrophage activation and subsequent release of cytokines 
Synthetic Immunostimulators 
Thymomimetics Levamisole hydrochloride Potentiates leukocyte stimulation by antigens, mitogens, etc. 
Interferon inducers Pyrimidinoles, Ampligen Induce IFN, activate macrophages and NK cells 




PROPHYLACTIC EFFECTS OF CAPRINE SERUM FACTOR (CSF-I) 
IN MICE INFECTED WITH SALMONELLA TYPHIMURIUM
INTRODUCTION 
Caprine Serum Fraction - Immunomodulator (CSF-I) is marketed as a non-
adjuvanted immunomodulator derived from goat serum. CSF-I is composed of a mixture 
of serum proteins and peptides and has a limited license for veterinary use (Ansley, 
1993). Field trials have shown efficacy of CSF-I against bacterial, viral, and 
environmental stress challenges as found in equine lower respiratory disease (Hamm et 
al., 2001), bovine shipping fever and respiratory disease, canine parvovirus and 
lymphoma, and ovine footrot (Ansley, 1993).  The broad spectrum of efficacy suggests 
that CSF-I may possess a general non-specific immunomodulator, enabling recipients to 
combat a variety of stress challenges. 
In mice, host-adapted salmonellae invade and multiply in the tissues of the 
reticuloendothelial system, with the severity and outcome of the disease dependent upon 
the infecting dose, the virulence of the bacterial strain, and the genetic background of the 
animal (Mastroeni et al., 1994; 1999). In lethal infections, bacterial proliferation in the 




infections, survival requires an early host response that controls the growth of the 
organism in the tissues (Maskell et al., 1987; Hormaeche et al., 1990). 
The purpose of this study was to assess whether CSF-I provides prophylactic 
benefit to mice systemically infected with Salmonella typhimurium. Six-week old, 
female Swiss Webster mice were injected i.p. with Salmonella typhimurium (~5.00 x 103 
bacteria/ mouse) on day 0, effectively establishing an LD80 by day 8 post-challenge. 
Some of the mice infected with S. typhimurium were also previously given subcutaneous 
injections of CSF-I. Mortality was compared between mice given no CSF-I and those 
provided CSF-I at various periods prior to infection.  Studies were performed in this 
manner to determine the optimal time of CSF-I administration and a CSF-I dose response 
profile. Spleens were examined for the presence of S. typhimurium so that the 
proliferation of pathogen could be compared among the groups, and blood samples 
collected during the course of this study were utilized for differential cell count analysis. 
MATERIALS AND METHODS 
Animal Care 
Four-week old, female Swiss Webster mice were purchased from Charles River 
Laboratories (Wilmington, MA).  The mice were acclimated for 2 weeks, during which 
time they were fed a standard maintenance diet, Laboratory Rodent Diet 5001 (PMI 
Feeds, Inc.), and watered ad libitum. Mice were group-housed (5 mice per cage) in 
plastic boxes bedded with wood shavings in an American Association for the 
Accreditation of Laboratory Animal Care (AAALAC)-accredited facility.  Mice were 
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transferred to an isolation room immediately after inoculation with S. typhimurium. The 
isolation room was maintained at 20oC in a controlled negative pressure environment on 
a 12 h lighting cycle. Animal care and use were in accordance with the policies of the 
Institutional Animal Care and Use Committee of Mississippi State University. 
Bacteria 
Salmonella typhimurium (ATCC 14028) was used as the challenge organism after 
passaging three times through a murine host with subsequent isolation and stored in 
phosphate buffered saline with 10% glycerol at -80oC. This isolate was supplied from a 
stock culture from the Department of Biological Sciences (Mississippi State University) 
where it is maintained as a reference organism.  Culture rehydration and cryoprotective 
maintenance conditions have been described previously (Darnell et al., 1987). 
Experimental Design 
Mice comprising the control (positive control) and treated populations were 
injected intraperitoneally (i.p.) with 0.1 ml of Salmonella typhimurium (~5 x 103 
bacteria/mouse) on day 0.  Unless stated otherwise, treated mice were given a 0.1 ml 
subcutaneous (sc) injection of CSF-I (Colorado Serum Co. - 30 mg protein/ml) at the 
time designated by the experimental protocol, while control mice received a placebo of 
physiological saline.  Negative control mice were sham handled in a similar manner to 
the control and treated populations to evaluate the influence of non-experimental 




were used per treatment group.  Mice were monitored three times daily and mortality 
recorded until 80% of the control mice died or for a maximum of two weeks. 
Systemic Proliferation of Salmonella 
Ten mice that had neither been treated with CSF-I nor exposed to S. typhimurium 
were euthanized by CO2 asphyxiation, their spleens harvested, and blood drawn from the 
inferior vena cava for differential cell count analysis.  Each spleen was weighed, diluted 
10-fold with sterile water, and homogenized. Aliquots of homogenate were plated on 
MacConkey agar, a medium selective for gram negative bacteria, and cultured overnight 
at 37oC. The number of S. typhimurium cfu were visually identified and the baseline 
value determined per g of spleen. Approximately 50 l of blood was streaked across a 
microscope slide, air dried, stained with Wright s stain (Fisher Scientific Company, 
Houston, TX), and a differential cell count analysis performed. 
Four treatment groups were established:  negative control (mice which received 
neither the bacterial challenge or CSF-I), positive control (mice which received the 
bacterial challenge but no CSF-I), CSF-I treated mice (mice which received both the 
bacterial challenge and CSF-I), and the treatment control (mice which received CSF-I but 
no bacterial challenge).  Each group was formed by randomly assigning a housing cage 
with five mice to a treatment regime until 14 cages were enrolled in the regime. 
CSF-I-treated mice were injected sc with 0.1 ml CSF-I on day -1.  The positive 
control and CSF-I treated populations were challenged with S. typhimurium on day 0. On 




their spleens harvested.  Blood was drawn from all treatment groups for analysis as 
described above. 
Differential Cell Counts 
Differential cell counts were determined on blood smears stained with Wright s 
stain. The lymphocytes, heterophils, monocytes, eosinophils, and basophils were 
identified by the morphological characteristics described by Lucas and Jamroz (1961). 
Baseline values were derived from averaging ten negative control mice.  Daily values for 
each treatment regime were assessed by averaging a minimum of 5 observations. 
Salmonella typhimurium Microagglutination Assay 
A Salmonella typhimurium microagglutination test along with its positive and 
negative control standards was purchased from the Center for Veterinary Biologics and 
National Veterinary Services Laboratories, United States Department of Agriculture 
(Ames, IA) and performed according to the testing protocol supplied. The titer of 
Salmonella antibody was determined for CSF-I (Colorado Serum Company) to help 
ascertain whether a sufficient titer was present to be responsible for the observed 
prophylactic benefits. 
The prophylactic benefit derived from administration of purified goat IgG (Sigma 
Chemical Company) was ascertained in accordance with the murine experimental model 
described above. Mortality observed in the population of control mice was compared to 
mice which received purified goat IgG (2 mg/mouse). 
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Limbulus amebocyte Lysate (LAL) Endotoxin Quantitation Assay 
The standardized endotoxic activity of CSF-I was determined by using an LAL 
gel clot assay by Associates of Cape Cod (Woods Hole, MA).  The threshold sensitivity 
of reaction was 0.03 endotoxic unit (EU) per ml. 
Statistical Analysis 
All experiments were arranged in a completely randomized design.  Data 
demonstrating cumulative mortality were analyzed using one way analysis of variance 
(ANOVA) with the general linear models procedure (Proc GLM) and the means 
separated by Fisher s projected LSD procedure (SAS Institute Inc., 1997).  A p value less 
than 0.05 was considered significant. 
RESULTS 
Salmonella typhimurium Microagglutination Assay 
The S. typhimurium microagglutination assay showed a positive reaction for up to 
a 1:8 CSF-I dilution in replicate testing (n = 3). 
LAL Endotoxin Quantitation Assay 
CSF-I had an endotoxin level of 0.31 EU/ml (0.01 EU/mg). 
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Multiple Administrations of CSF-I 
Onset of mortality occurred approximately 4 days post-challenge.  It was of 
interest to determine whether the survival rate could be improved with supplemental 
administrations of CSF-I.  Control mice were compared to two treated groups: one which 
received CSF-I only on day 0 and another which received CSF-I on days 0, 1, and 4 
(Figure 2.1). Both treated groups had significantly fewer deaths than the control 
population between days 5 and 8.  There was no significant difference in prophylactic 
benefit between the populations which received the single or multiple administrations of 
CSF-I.  On day 7, the day 0 and days 0, 1, and 4 treated groups had a mortality of 17% 
and 14%, respectively. 
Optimal Time of CSF-I Administration 
A single dose of CSF-I was administered at various times prior to challenge to 
assess persistence of positive effects and to ascertain the optimal time of administration 
with regard to the S. typhimurium challenge model.  CSF-I was administered on either 
day -4, -2, -1, or coincident with the challenge on day 0 (Figure 2.2).  Three to four days 
were usually required before deaths were observed in control populations of female 
Swiss Webster mice challenged with S. typhimurium (~5 x 103 bacteria/mouse). A rapid 
rise in death ensued with ~80% mortality occurring 1 week post-challenge and ~90% 
mortality on day 8. Mice treated with CSF-I four days prior to challenge showed no 
significant difference from this pattern.  Prophylactic benefit, however, was observed if 
CSF-I was given on either day -2 or 0.  One week post-challenge, the control population 
14 
presented 83.3% mortality, while groups that received CSF-I on either day -2 or 0 had 
percent mortalities of 13.3 and 16.7, respectively. On day 8 these values rose to 90 
(control), 36.7 (day -2), and 23.3 percent (day 0).  Mice treated one day prior to challenge 
had the least number of deaths. Only 10% of this treated group were dead at days 7 and 
8 post-challenge.  Beginning with day 5 post-challenge (when mortality was established 
in the control population) there was a statistically significant difference between the 
control group and each of the day -2, -1, and 0 CSF-I treated groups.  The day -1 
treatment group was also significantly different from the day 0 and day -2 CSF-I 
populations. 
Dose Response to CSF-I 
A dose response study was performed in order to determine the optimal amount 
of CSF-I to administer for prevention of mortality (Figure 2.3).  CSF-I was prepared so 
that a 0.10 to 0.25 ml i.p. injection would deliver either 0.3, 1.5, 3.0, or 7.5 mg CSF-I. 
All injections of CSF-I were given on day -1, as this was shown by the time course study 
to produce the greatest prophylactic benefit.  On day 7, all doses were significantly 
different (p < 0.05) from the control mice except for the 0.3 mg CSF-I dosage.  Seventy-
seven percent of the control population died by day 7, while with respect to increasing 
amounts of CSF-I, 60, 33, 27, and 17% had died in these treated groups. 
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Systemic Proliferation of Salmonella 
A 6 to 7 thousand fold increase in S. typhimurium was found in the spleens of 
control mice 2 to 3 days after pathogenic challenge (Table 2.1). Spleens were friable by 
day 3 and numerous grey white lesions visible.  The proliferation of S. typhimurium went 
seemingly unchecked.  There was an approximate 50,000-fold increase by day 4 which 
continued to escalate to a 2-3 million fold increase over the following three days.  Mice 
treated with a single dose of CSF-I one day prior to challenge had no increase in S. 
typhimurium by day 2, and had less than a 100 fold increase on days 3 and 4.  Treated 
mice retained a significant difference in S. typhimurium population on day 5 (over 700 
fold less than control mice) but this margin narrowed to only a 5 fold difference by day 7. 
Differential Cell Counts 
A significant decrease in lymphocytes between positive control and baseline mice 
was noted beginning on day 3 and continued throughout the study.  However, no 
significant difference was noted between CSF-I treated and baseline mice until day 5 
(Figure 2.4a). On day 7, there was a 67% decrease in the percent lymphocyte count of 
positive control mice, while CSF-I treated mice only showed a decrease of  26%. There 
was no significant difference on any day between any treatment regime group and 
baseline mice for eosinophil or basophil counts. Further, analyses of the negative control 
and treatment control samples showed that none of the blood parameters tested were 




Control mice showed a significant increase in percent neutrophil composition by 
day 2. A significant increase in both neutrophils (Figure 2.4b) and monocytes (Figure 
2.4c) was noted in control mice by day 4 (269% and 279%, respectively).  These values 
continued to increase throughout the observation period culminating at day 7 (461% and 
369%, respectively).  During this seven day period, neutrophil values for CSF-I treated 
mice increased 206%, and at no time were the monocyte counts significantly different 
from baseline values. Positive control mice also had a much greater percent of 
neutrophils showing toxic changes as evidenced by their foamy, vacuolated cytoplasm 
(73% versus 7% for CSF-I treated mice). 
DISCUSSION 
Post-operative patients and individuals with auto-immune dysfunction have been 
treated therapeutically with -globulin (Duswald et al., 1980; Berkman et al., 1990), 
administration which has also proved efficacious when used to treat the auto-immune 
disorders of antiphospholipid syndrome and systemic lupus erythmatosus developed in 
murine experimental models (Bakimer et al., 1993; Krause et al., 1995). CSF-I has a 
significant globulin presence and tested positive for Salmonella IgG up to 8-fold dilution. 
When purified goat IgG was administered as the sole prophylactic agent to combat 
salmonellosis, the mice responded in a manner consistent with control mice.  While 
globulin is a functional participant of the immune system and has been shown to offer 
some therapeutic benefit, no mechanistic role could be ascribed to its administration in 




A n i n o c ul u m s tit er of pat h o g e nic or g a ni s m s gr e atl y i nfl u e n c e s w het h er a l et h al 
c h all e n g e d e v el o p s.  H o st a bilit y t o q ui c kl y r e d uc e t h e n u m b er of i nf e cti n g or g a ni s m s 
h el ps pr e v e nt t h e i n e vit a bl e e x p o n e nti al gr o wt h p h as e fr o m pr o c e e di n g i n a n 
u nr e str ai n e d m a n n er, a n e ss e nti al el e m e nt f or h o st s ur vi v al ( M a str o e ni et al. , 1 9 9 9). 
A nti- mi cr o bi al p e pti d e s s u c h a s d efe n si n s, f o u n d i n pl a s m a oft e n b o u n d t o pl a s m a 
pr ot ei ns, h el p s er v e t his r ol e ( P a n y uti c h et al. , 1 9 9 3).  D ef e nsi ns c o ul d e asil y b e 
c o n c e ntr at e d d uri n g t h e a m m o ni u m s ulf at e fr a cti o n ati o n pr o c e d ur e us e d t o m a n uf a c t ur e 
C S F-I.  C a pri n e s er u m a n d t h e l ar g e ( 1 0 k D a) a n d s m all ( 1 0 k D a) m ol e c ul ar w ei g ht 
m at eri al fr a cti o n at e d fr o m it b y si z e filtr ati o n w er e s cr e e n e d f or b a ct eri ci d al a cti vit y 
a g ai n st a s e ri es o f gr a m p ositi v e a n d gr a m n e g ati v e b a ct eri a i n cl u di n g S al m o n ell a 
t y p hi m uri u m usi n g dis k a g ar diff usi o n ass a ys ( Will ef or d et al., 2 0 0 0).  Ba ct eri ci d al 
a cti vit y w a s n ot f o u n d i n a n y of t h e s e pr o d u ct s a n d t h er ef or e it i s l o gic al t o c o n cl u de t h at 
C S F-I s pr o p h yl a cti c b e n efit is n ot a f u n cti o n of a t y pi c al d ef e nsi n-li k e a cti o n.  
T h e s yst e mi c n at ure of t h e S. t y p hi m uri u m  i nf e cti o n w as m o nit or e d b y 
d et er mi ni n g its pr olif er ati o n i n s pl e ni c tiss u e a n d eff e cts o n t h e l e u k o c yt e pr ofil e. T h e 
o ns et of m ort alit y w as c oi n ci d e nt wit h a b a ct eri al c o u nt of a p pr o xi m at el y 1 0 6  cf u/ g 
s pl e e n.  C o ntr ol mi c e r e a c h e d t his l e v el 4 d a ys p ost- c h all e n g e, b ut C S F-I tr e at m e nt 
h el p e d a b at e p at h o g e ni c pr olif er ati o n, pr e v e nti n g a l et h al l e v el fr o m b ei n g r e a c h e d u ntil 
d a y 6.  T h e d el a y/r e d u cti o n i n m ort alit y o b ser v e d i n tr e at e d p o p ulati o n s of mi c e m a y 
h a v e r es ult e d fr o m C S F-I s a bilit y t o r e a d y or sti m ul at e t h e h ost s i m m u n e s yst e m f or 
a cti o n.  M a xi m al r e s p o n se o c c urr e d w h e n C S F-I w a s a d mi ni st er e d 1 d a y pri or t o 
c h a ll e n g e, b u t si g nifi c a nt  b e n efi t w a s o b s er v e d w h e n C S F-I w a s gi v e n e it h er 2  d a ys 
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before challenge or coincident with the challenge. Clearly, benefit did not extend beyond 
4 days in the lethal model used here. 
It is also apparent that there is an upper level to the ability of CSF-I to stimulate 
the immune system.  No significant difference was observed 8 days after challenge in 
mice which received either the 3 or 7.5 mg dose of CSF-I one day prior to challenge. 
The dose response curve had plateaued. In addition, no benefit (as measured by 
survivability) was noted in mice which received several  booster  doses of CSF-I.  This 
may be because the amount of CSF-I used in this experiment generated a near maximal 
activation of the immune response which then persisted for several days. An analogous 
dose response profile was observed when CSF-I was used to therapeutically treat horses 
suffering from lower respiratory disease (Hamm et al., 2001) 
Microbial infection alters the  normal  leukocyte profile to reflect the adaptive 
needs of the host. Neutrophils are rapidly deployed to the infection site followed by 
monocyte accumulation to phagocytose pathogens (Tizard, 1996).  The stress response 
initiated by microbial infection therefore consists partially of neutrophilia, monocytosis, 
lymphopenia and inflammation (Zinkl, 1981; Latimer and Rakich, 1989; Maxwell, 
1993). The leukocyte profile revealed by differential cell count analysis showed that 
control mice experience significant neutrophilia by day 2, monocytosis by day 4 and 
lymphopenia by day 3. Monocytosis was not evident in CSF-I treated mice throughout 
the 7 day observation period and significant neutrophilia and lymphopenia were each 
delayed by two additional days.  These observations correlate with the bacterial 
proliferation data and mortality response.  Treated mice were better able to respond to 
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t h e c h all e n g e p e r mitti n g t h e h ost t o m o u nt a s u c c essf ul d e f e ns e a n d cl e a r t h e or g a nis m 
fr o m it s s y st e m.  W hil e t h e l e u k o c yt e pr ofil e of mi c e s ol el y tr e at e d wit h C S F-I w a s 
u n c h a n g e d, t h e r e ci pi e nt s st at e of r e a di n ess m a y h a v e b e e n h ei g ht e n e d.  U p o n a 
r e c o g ni z e d c h all e n g e ( e. g., L P S sti m ul ati o n) t h e h ost s i m m u n e s yst e m m a y r es p o n d 
m or e r a pi d l y a n d vi g or o usl y. 
S u bl et h al i nf e cti o ns of S al m o n ell a  m a y pr oc e e d i n f o ur di sti n ct p h a s e s: (i) a n 
e arl y i n a cti v ati o n of t h e c h all e n g e i n t h e first 2 4 h; (ii) e x p o n e nti al gr o wt h; (iii) t h e 
pl at e a u p h as e; a n d (i v) T- c ell d e p e n d e nt b a ct eri al cl e ar a n c e ( H or m a e c h e, 1 9 7 9; 
H or m a e c he et al. , 1 9 8 5).  T h e st u di es r e p ort e d h er e s u g g est t h at C S F-I c a n e x ert 
i nfl u e n c e pri or t o a cti v ati o n of t h e a d a pti v e i m m u n e r e s p o ns e.  It is p ossi bl e t h at C S F-I 
m a y dir e ctl y m o d ul at e t h e b a ct eri ci d al a cti viti es of m a cr o p h a g es h ar b ori n g S al m o n ell a 
b y a cti vati n g N K c ell s - w hi c h ar e k n o w n t o p arti ci pat e i n r e si st a n c e a g ai nst mi cr o bial 
i nf e cti o n ( Ti m o n e n, 1 9 9 7), or p ossi bl y t hr o u g h m o d ul ati o n of m a cr o p h a g e f u n cti o n 
t hr o u g h n at ur al kill er c ell- d eri v e d c yt o ki n es s u c h as I F N-  ( K a g a ya et al. , 1 9 8 9; 
R a m ar at hi n a m et al. , 1 9 9 3). 
T h e s e ar c h f or a g e nt s w hi c h p ot e nti at e t h e i m m u n e r e s p o n s e i s a dri vi n g f or c e i n 
dr u g r e s e ar c h.  Us e of i m m u n e r e g ulati n g or i m m u n e m o d ul ati n g m ol e c ul e s s h o ul d 
i n d u c e a st at e of g e n er al h y p er a cti vit y of t h e i m m u ne s y st e m w hi c h s h o ul d pr e ci pit at e 
a n d/ or e n h a n c e t h e pr o p h yl a cti c r e s p o n se t o i m m u n e c h all e n g e s s u c h a s p at h o g e ni c 
i nf e cti o n.  If s u c h a n o n-s p e cifi c i m m u n e r es p o ns e c o ul d b e i niti at e d at will, it c o ul d b e 
utili z e d t o eit h er a ct al o n e or i n c o n c ert wit h c o n v e nti o n al tr e at m e nts dir e c t e d t o w ar ds 
eti ol o gi c al a g e nt s.  C S F-I a p p e ar s t o p o ss e s s a n i m m u n o m o d ul at or y c o m p o u n d.  T hi s 
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agent does not appear to derive its prophylactic benefit from direct bactericidal activity 
or the direct action of administered globulin. It is unclear whether administration of 
CSF-I affects the ability of the host to kill the bacteria, control their subsequent rate of 
growth, or both. CSF-I, however, influences in a positive way the ability of the host to 
withstand and survive a challenge of an infectious agent.  Further investigation is 
required to determine the nature of the immune-regulatory compound and elucidate its 
mode of action. 
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Table 2.1. Systemic proliferation of Salmonella typhimuriuma 
Treatment  S. typhimurium cfu/g of spleen (x 105) 
Day after Salmonella Inoculation 
2  3 4 5 6 7 
Control 3.7 ± 0.8b 2000 ± 100b 890 ± 100b 1400 ± 200b 3.2 ± 0.5b 24 ± 2b 
45 ± 6bCSF-I  0.0005c 0.04 ± 0.03 c 0.02 ± 0.02c 2.8 ± 0.7c 300 ± 120b 
aControl mice were administered 0.1 ml (5 x 103 cfu) of S. typhimurium i.p. on day 0, while treated mice received both 
S. typhimurium on day 0 and a 0.1 ml sc injection of CSF-I (3 mg) on day -1.  Spleens were harvested on days 2 through 7, 
homogenized and assessed for S. typhimurium. Each data point represents the average bacterial count/g of spleen ± SEM 
(n 5). A minimal cfu value of 100 was required to be detectable. S. typhimurium were not detected in baseline mice 
(n = 10) or on day 2 of the CSF-I treated population.  A value of 50 was assigned to these populations in order to permit 
comparisons between groups. 
b-cMeans within a column lacking a common superscript differ (p < 0.05). 
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Figure 2.1. Effect of post-challenge administration of CSF-I.  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 
(open bar), while treated mice received both S. typhimurium on day 0 and a 0.1 ml sc 
injection of CSF-I (3 mg) on either day 0 (closed bar), or on days 0, 1, and 4 (hatched 
bar). Each data point represents the average cumulative mortality (n = 6) per cage of 5 
mice. 
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Figure 2.2. Optimal time of CSF-I administration (time course profile).  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 
(open bar), while treated mice received both S. typhimurium on day 0 and a 0.1 ml sc 
injection of CSF-I (3 mg) either on day -4 (closed bar), day -2 (hatched bar), day -1 
(cross-hatched bar), or day 0 (shaded bar).  Each data point represents the average 
cumulative mortality (n = 6) per cage of 5 mice. 
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Figure 2.3. CSF-I dose response profile.  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 
(open bar), while treated mice received both S. typhimurium on day 0 and a sc injection 
of either 0.3 mg (closed bar), 1.5 mg (hatched bar), 3.0 mg (cross-hatched bar), or 7.5 mg 
(shaded bar) CSF-I.  Each data point represents the average cumulative mortality (n = 6) 
per cage of 5 mice. Means with no common letter differ significantly (p < 0.05). 
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Figure 2.4. A comparison of differential cell counts between CSF-I treated and control 
mice after challenge with Salmonella typhimurium. 
Ten mice that had been neither treated with CSF-I nor exposed to S. typhimurium were 
euthanized and approximately 50 l of blood was streaked across a slide for differential 
cell count analysis.  The cellular identification of 100 leukocytes was performed based 
on morphological characteristics as described by Lucas and Jamroz (1961).  Control (+) 
and CSF-I ( ) treated mice were prepared in accordance with the experimental design 
in Materials and Methods, as were the negative control ( ) and treatment control ( ) 
mice. On days 2 through 7, a minimum of five mice from each group was randomly 
selected and blood drawn for differential cell count analysis.  The percent cell type ± 
SEM was determined for a) lymphocytes, b) neutrophils, and c) monocytes. 
C H A P T E R III 
R E D U C TI O N I N L A Y E R M O R T A LI T Y B Y A C A P RI N E S E R U M F R A C TI O N 
I N T R O D U C T I O N 
Di s c o v eri n g a g e nt s w hi c h p ot e nti at e t h e i m m u n e r e s p o n s e is a dri vi n g f or c e i n 
dr u g r es e ar c h.  C yt o ki n es a n d c ati o ni c p e pti d es ar e t w o cl ass es of  r el ati v el y l o w 
m ol e c ul a r w ei g ht c o m p o u n d s w hi c h h a v e s h o w n pr o mi s e i n t his ar e a of r es e a r c h.  At 
l e a st ni n e i m m u n o- d efe n s e p e pti de pr o d u ct s ar e alr e a d y o n t h e m ar k et wit h a n n u al s al e s 
of o v er $ 4 billi o n ( L at h a m, 1 9 9 9). 
I nt erl e u ki n- 1 (I L- 1), t u m or n e cr osis f a ct or-  ( T N F- ), a n d i nt erf er o n (I F N) ar e 
t hr e e c yt o ki n e s w hi c h p arti ci p at e i n t h e i m m u ne r e s p o n s e.  I L- 1 i s i n v ol v e d i n t h e h o st s 
r es p o ns e t o a nti g e ni c c h all e n g e a n d tiss u e i nj ur y, a n d h as b e e n s h o w n t o i n cr e as e t h e 
r esist a n c e of mi c e t o p at h o g e ni c or g a ni s ms s u c h as Li st e ri a , E s c h e ri c hi a c oli , a n d 
C a n di d a al bi c a ns  ( C z u pr y ns ki a n d Br o w n, 1 9 8 7; Cr oss et al. , 1 9 8 9;  P e c y k et al., 1 9 8 9). 
T N F-  a n d  -I F N w er e a bl e t o i n cr e as e t h e r esist a n c e of mi c e t o S al m o n ell a 
t y p hi m uri u m ( M orriss e y a n d C h arri er, 1 9 9 4).  H u m a n I F N- s h a v e p ot e nt a nti vir al a n d 
a nti pr olifer ati v e a cti viti e s, a n d ar e c urre ntl y bei n g utili z e d a s a nti vir al or a nti c a n c er 




Some cationic peptides have also been observed to act as an immunostimulant. A 
decameric peptide was shown to impede the growth and spreading of established tumors 
(Folkman, 1999).  Other peptides promote antibacterial, antifungal, antiviral, and even 
wound healing properties (Hancock, 1999; Mizuno et al., 1995; Sanglier et al., 1993).  It 
is believed that these  defense  peptides are more general in their actions than 
antibodies, and as such, have a broader range of activity (Hancock, 1999). 
Because cells of the immune system circulate through the blood and lymphatic 
system, serum is a logical place to look for immunomodulators. To date, about half of 
the over 100 serum proteins have been isolated and characterized (de Gruyter, 1997). 
Caprine Serum Fraction - Immunomodulator (CSF-I, US Patent 5,219,578.) is a 
nonadjuvanted immunomodulator derived from goat serum.  CSF-I remains ill-defined 
but is composed of a mixture of serum proteins and peptides. 
It is important to develop rapid and reliable screening assays for the isolation and 
characterization of the components in CSF-I responsible for potentiating the immune 
response.  TNF-  bioassays proved to be unreliable.  Along with the pursuit of  effective 
screening assays, the development of reliable animal models by which to confirm the 
presence of the compound of interest continues.  This study presents an avian model 
which can be performed reliably over a two to seven day period.  This is also the first 
study to show that material fractionated from goat serum helps retard pathogenesis due to 
bacterial infection in a non-mammal, supporting the belief that CSF-I is a nonspecific 
immunomodulator. 
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MATERIALS AND METHODS 
Animal Husbandry 
Fertile eggs obtained from specific-pathogen-free (SPF) Leghorn chickens 
(HY-Vac Laboratory Eggs, Co., Adel, IA, 50003) were incubated under standard 
conditions. Upon hatch, 120 chickens were equally and randomly assigned to each of 12 
Horsfall-Bauer isolation units. Birds were raised in this manner until they were 5 weeks 
of age, at which time the Pasteurella challenge was administered. Bird density was 360 
cm2 per bird at 5 weeks. All chickens had ad libitum access to feed and water. Birds 
were fed a standard pullet starter diet that met or exceeded National Research Council 
(1994) recommendations. The isolation room was a negative pressure environment 
maintained at 25oC with a 12 h light:12 h darkness cycle. 
Bacteria 
Pasteurella multocida X-73 (serotype 1) was obtained from the National Animal 
Disease Center, Ames, Iowa. P. multocida was grown in brain-heart infusion (BHI) 
broth (Difco Laboratories, Detroit, MI) at 37oC. After 16 h incubation, 1 ml of culture 
was transferred to 100 ml of fresh BHI broth and incubated at 37oC for 4 h. The bacterial 
culture was serially diluted with sterile water in 10-fold increments.  Each dilution was 
plated on blood agar plates and the colonies counted after 24 h incubation to determine 
the number of cfu (Wang and Glisson, 1994). 
Pasteurella multocida P-1581, Pasteurella multocida ATCC 11039, 
Pseudomonas aeruginosa ATCC 27853, Pseudomonas aeruginosa PAO1, Escherichia 
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coli ATCC 25922, Enterobacter aerogenes, Enterobacter cloacae, Salmonella 
typhimurium, Staphylococcus aureus, Staphylococcus aureus T-5706, and Bacillus 
subtilis were supplied from stock cultures by Dr. F. R. Champlin (Department of 
Biological Sciences, Mississippi State University) where they are maintained as 
reference organisms. Culture rehydration and cryoprotective maintenance conditions 
have been described previously (Darnell et al., 1987). 
Preparation of Caprine serum fraction - immunomodulator 2 (CSF-I2) 
CSF-I2 was fractionated from goat serum by collecting the material which flowed 
through a dialysis membrane (Spectrum Laboratories, Inc., Laguna Hills, CA) with a 
molecular weight cut-off of 6-8 kDa.  This low molecular weight material was 
lyophilized to a powder and stored at -70oC until reconstituted with water for use. 
Powdered CSF-I2 was 37.5% proteinaceous based on its nitrogen content.  
Susceptibility Assays 
Caprine serum and its high (  8 kDa) and low molecular weight ( 8 kDa) 
subfractions (each at a protein concentration of 20 mg/mL) were assessed for 
antimicrobial activity against both gram positive and gram negative bacteria by 
performing disk agar diffusion assays as described in Hart and Champlin (1988). 
Antibiotic minimum inhibitory concentrations (MICs) were determined in Mueller-
Hinton broth (Difco Laboratories, Detroit, MI) using the broth dilution method described 
previously (Darnell et al., 1987). Caprine serum and its dialysate ( 8 kDa) were unable 
 
30 
to inhibit bacterial growth.  CSF-I2, material presumed to contain small molecular 
weight immunomodulatory agents, also failed to inhibit the growth of all test bacteria, 
including two serotypes of Pasteurella (Table 3.1). 
Bird Treatment 
Two of 12 housing units were utilized as stress control pens.  Birds assigned to 
these units did not receive a bacterial challenge or CSF-I2, but were sham handled in a 
manner consistent with all other birds. All inoculated birds received 18-30 cfu of 
Pasteurella multocida (X-73 strain, serotype 1) on day 0. CSF-I2 and sham treatments, 
as well as bacterial challenges, were administered as 0.5 ml intramuscular (i.m.) 
injections. 
Control birds housed in five of the remaining ten units received Pasteurella and 
sham treatment in a manner consistent with CSF-I2 treated birds. In experiment 1, 
treated birds were given 0.5 ml of a 10 mg/ml CSF-I2 solution (5 mg) on days -1 and 0. 
In the second experiment the treated birds received 0.5 ml of a 20 mg/ml CSF-I2 solution 
(10 mg) on days -1 and 0.  Treated birds in the third experiment received 0.5 ml of a 
20 mg/ml CSF-I2 solution (10 mg) on days -1, 0, and +1.  The number of deaths were 
recorded and dead birds were removed from each unit at the same time each day.  Each 
experiment utilized a seven day trial period wherein the average cumulative mortality per 




Birds used in Experiment three were banded for identification. Five birds were 
selected at random from both the control and CSF-I2 treated populations. Two ml of 
blood was drawn from a wing vein and immediately processed for CD4 and CD8 counts. 
Blood was drawn 1 week prior to the Pasteurella challenge in order to establish a 
representative baseline count. Blood was also collected on day 1 in order to assess how 
the challenge and CSF-I2 treatment may alter these immunological parameters. 
The CD4 and CD8 lymphocyte subset percentages in the peripheral blood were 
enumerated using a modification of a previously published method (Ainsworth et al., 
1990). Briefly, Ficoll-Paque isolated peripheral blood leukocytes were incubated with 
FITC-conjugated mouse anti-chicken CD4 or RPE-conjugated mouse anti-chicken CD8, 
or the appropriate isotype-matched control conjugates (Southern Biotechnology 
Associates, Inc., Birmingham, AL).  Modifications to the procedure included a reduction 
of the incubation times to 5 min and analysis of samples using a FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, CA). 
Differential Cell Counts
A total of 200 nonerythroid, nonthrombocytic leukocytes were counted on 
duplicate blood smears stained with Wright s stain (Sigma Chemical Co., St. Louis, 
MO). The lymphocytes, heterophils, monocytes, eosinophils, and basophils were 
identified by the morphological characteristics described by Lucas and Jamroz (1961), 
and the relative percentage of each identified cell type reported. 
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St ati sti c al A n al y si s 
All e x p eri m e nt al pr ot o c ol s r e q uir e d a c o m pl et el y r a n d o mi z e d d e si g n.  D at a 
d e m o n str ati n g c u m ul ati v e m ort alit y a n d di a g n osti c bl o o d p ar a m et er s w er e a n al yz e d 
usi n g o n e w a y a n al ysis of v ari a n c e wit h t h e g e n er al li n e ar m o d els pr o c e d ur e ( Pr o c G L M) 
a n d t h e m e a ns s e p ar at e d b y Fis h er s pr oj e ct e d L S D pr o c e d ur e ( S A S I nstit ut e I n c., 1 9 9 7). 
A pr o b a bilit y l e s s t h a n 0. 0 5 h a d t o be r e a c h e d i n or d er t o b e c o n si d er e d si g nifi c a nt. 
R E S U L T S
 Bir d s re c ei vi n g t h e 5 m g C S F-I 2 tr e at m e nt re gi m e o n da y s - 1 a n d 0 d e m o nstr at e d 
si g nifi c a ntl y l ess m ort alit y t h a n i n o c ul at e d c o ntr ols t hr o u g h o ut t h e st u d y p eri o d ( Fi g ur e 
3. 1).  H o w e v er, t h e gr e at est diff er e n c e w as o bs er v e d wit hi n t h e first 4 8 h aft er c h all e n g e. 
D uri n g t his 2 d a y p eri o d, t h e c o ntr ol gr o u p r e c ei vi n g 3 0 cf u of P. m ult o ci d a  dis pl a y e d t h e 
gr e at est m ort alit y.  F ort y- ni n e p er c e nt of t h e c o ntr ol p o p ul ati o n w er e d e a d aft er 2 4 h a n d 
9 1 % w er e d e a d b y d a y 2.   T h e 5 m g C S F-I 2 tr e at m e nt r e gi m e, h o w e v er, si g nifi c a ntl y 
r et ar d e d p at h o g e n e si s of t h e P ast e ur ell a i nf e cti o n.  M ort alit y i n C S F-I 2 tr e at e d bir ds 
w er e 6 a n d 5 6 % o n d a ys 1 a n d 2, r es p e cti v el y.  M ort alit y gr a d u all y i n cr e as e d t o 7 8 % 
o v er t h e f oll o wi n g 5 d a ys of t h e st u d y p eri o d.  
P at h o g e n esis w as r et ar d e d f urt h er w h e n t h e C S F-I 2 d os e r e gi m e w as d o u bl e d t o 
1 0 m g ( Fi g u r e 3. 2 ).  A P a st e u r ell a  c h all e n g e of 1 8 cf u c a us e d r a pi d m ort alit y i n t h e 
c o ntr ol p o p ul ati o n ( 6 0 % a n d 8 0 % f or d a ys 1 a n d 2, r es p e cti v el y). M ort alit y i n t h e 
c orr es p o n di n g C S F-I 2 tr e at e d gr o u p w as o nl y 0 a n d 1 3 % o n d a ys 1 a n d 2, r es p e cti v el y. 
M ort alit y o n d a y 7 h a d ris e n t o 3 3 %, w hi c h w as si g nifi c a ntl y l ess t h a n t h at of t h e c o ntr ol 
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population (83%), and was less than that observed when the 5 mg CSF-I2 treatment 
regime was used. 
The 10 mg CSF-I2 treatment regime was extended to include an additional 
delivery dose on day 1 (after the daily observation).  Twenty-eight cfu of Pasteurella 
were used to initiate pathogenesis. After 24 h, mortality in the CSF-I2 treated population 
was significantly less than that of the control population (12% and 77%, respectively; 
Figure 3.3). Mortality on days 2 and 7 in CSF-I2 treated birds (38% and 56%, 
respectively) were consistently lower than that found in the corresponding untreated 
control population (94% and 97%, respectively). 
Both treatment regimes utilizing 10 mg of CSF-I2 allowed birds to survive the 
bacterial challenge better than the 5 mg CSF-I2 treatment regime (Figure 3.4).  There 
was no evidence, however, which showed that the additional administration of CSF-I2 on 
day 1 initiated a significantly better response than the 2 day dose regime of 10 mg 
CSF-I2. 
The blood levels of CD4 and CD8 cells in unchallenged SPF chickens of Trial 3 
were 18 and 26%, respectively.  The microbial challenge caused the day 1 CD4 cell 
count to decrease to 10% (p < 0.05) while birds treated with CSF-I2 expressed a CD4 cell 
count of 21% (not significant).  No appreciable changes in CD8 levels occurred due to 
CSF-I2 treatment.  
The highest rate of mortality due to Pasteurella pathogenesis occurred within the 
first 24 h. Differential cell counts were taken for control and CSF-I2 treated birds at 24 h 
and compared to baseline values (Table 3.2).  Control birds showed a significant drop in 
34 
lymphocytes and increase in heterophils.  CSF-I2 treated birds showed the same trends in 
lymphocytes and heterophils; however, the changes were not as severe.  Although the 
differences were significant, it is unknown as to how indicative these values are because 
of the small sample size and high death rate, which made it impractical to follow the 
same birds throughout the study.  There were no significant differences in monocytes, 
basophils, and eosinophils between CSF-I2 treated and control birds. 
DISCUSSION 
Agents which retard pathogenesis may enable a host to mount a successful 
defense to challenges of the immune system.  These agents can provide specific 
protection (i.e., in the form of antibodies) or be general in nature and enhance overall 
immunocompetence. Cytokines and cationic peptides are two such classes of non-
specific defense agents.  CSF-I is a non-adjuvanted immunomodulator derived from goat 
serum containing a mixture of serum proteins and peptides. Identifying the immuno-
active components in CSF-I (and therefore goat serum) requires a bioassay.  The 
Pasteurella challenge model utilized in this study was shown to be an effective bioassay 
in chickens. 
Immunoglobin and albumin are the two most abundant serum proteins.  The size 
fractionation procedure employed removed proteins with a molecular weight greater than 
8 kDa. Therefore, it excluded immunoglobin, albumin, and most cytokines.  This 
composite of low molecular weight material (CSF-I2) was unable to inhibit growth of 
gram-negative and gram-positive bacteria.  The minimum inhibitory concentration (MIC) 
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for a cationic peptide is usually in the range of 1 to 8 g/mL (Hancock, 1997). Two 
serotypes of Pasteurella showed no zone of growth inhibition when CSF-I2 was tested at 
20 mg/mL, over 2,500 times the upper MIC range recognized for cationic peptides. 
SPF layer chickens experience a severe rate of mortality when challenged by low 
doses (18 to 30 cfu) of P. multocida X-73 (serotype 1).  CSF-I2 was, however, able to 
significantly retard Pasteurella pathogenesis and promote higher survivability in SPF 
chickens.  Three treatment regimes of CSF-I2 were examined in this study: 5 mg CSF-I2 
(i.m., days -1 and 0), 10 mg CSF-I2 (i.m., days -1 and 0), and 10 mg CSF-I2 (i.m., days -
1, 0, and 1). All treatments effectively reduced mortality through 1 week post-challenge. 
The 10 mg CSF-I2 dose regimes, however, clearly performed better than the 5 mg CSF-I2 
dose regime.  Variances in experimental parameters make a rigorous statistical 
comparison between the two 10 mg CSF-I2 dose regimes impossible.  However, there 
was no evidence that day 1 administration of CSF-I2 improved survivability.  This may 
be because the amount of CSF-I2 used on days -1 and 0 had generated a near maximal 
activation of the immune response which then persisted for a period of time. 
Heterophils are the first line of defense.  They are the earliest phagocytic cells to 
be recruited to a site of infection, and usually only survive for a few hours after leaving 
the bone marrow (Bancroft et al., 1997). The elevated heterophil count found in control 
birds may indicate a need for their continued release as these birds were unable to clear 
the pathogen, evidenced by the high rate of mortality.  Treated birds, however, expressed 
a lower heterophil count, indicating that they were better able to combat the infection. 
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CD4s are associated with Helper T cells, while CD8s are associated with killer 
cells, which kill other cells and may suppress the immune response (Tizard, 1992). The 
control birds expressed a large decrease in lymphocytes, thus leading to the drop in CD4 
counts. An elevated CD4 count (as seen in CSF-I2 treated birds) implies increased 
lymphocyte reactivity as helper cells predominate, whereas a high CD8 level implies 
decreased lymphocyte reactivity as a result of excessive suppressor activity (Tizard, 
1992). The prevention of a drop in CD4s by CSF-I2 may indicate an increased immune 
response, thus leading to decreased mortality. 
An avian model was developed which permits assessment of the immuno-activity 
present in CSF-I2 within a 2 day period, thus establishing means by which the immuno-
active components can be isolated and characterized.  Furthermore, because the agent(s) 
present in CSF-I2 significantly reduced SPF mortality given a severe microbial challenge, 
the immuno-active components may offer even a higher degree of protection against less 
virulent pathogens.  The mechanism by which CSF-I2 precipitates its immuno-effect is 
unclear. Nevertheless, our preliminary evidence indicates that one possible route by 
which CSF-I2 sustains an immunocompetent status is by maintaining the presence of 
Helper T cells in serum. 
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Table 3.1. Susceptibility of selected bacteria to growth inhibition by caprine serum 
fractionated into its high (>8 kDa) and low (<8 kDa) molecular mass (MM) components 
Organism 
Gram-negative bacteria 
Pseudomonas aeruginosa ATCC 27853 
Zone of inhibition1 
Low MM  High MM 
4 h 24 h 4 h 24 h 
0 0 0 0 
Pseudomonas aeruginosa PAO1 0 0 0 0 
Escherichia coli ATCC 25922 0 0 0 0 
Enterobacter aerogenes 0 0 0 0 
Enterobacter cloacae 0 0 0 0 
Salmonella typhimurium 0 0 0 0 
Pasteurella multocida ATCC 11039 IG2 0 IG 0 
Pasteurella multocida P-1581 IG 0 IG 0 
Gram-positive bacteria 
Staphylococcus aureus 0 0 0 0 
Staphylococcus aureus T-5706 0 0 0 0 
Bacillus subtilis IG 0 IG 0 
1Mueller-Hinton agar plates were streak inoculated with each of the assay organisms. 
Sterile filter paper disks impregnated with either the high or low molecular weight 
caprine serum fraction were aseptically applied to the seeded plate surfaces.  The plates 
were incubated for 24 h at 37oC, during which time inhibition of growth in areas 
surrounding the disks were visually assessed at 4 and 24 h.  
2IG = insufficient growth. 
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Table 3.2. A comparison of differential cell counts of control and CSF-I2 treated birds 
24 h after challenge with Pasteurella multocida with their established baseline1 
Lymphocytes Heterophils Monocytes Basophils Eosinophils 
baseline 69.83a 23.21b 2.53b 2.78a 1.64a 
control 41.09c 46.95a 8.27a 1.43b 2.26a 
treated 58.12b 32.52b 6.56a 1.50ab 1.30a 
a-cMeans in a column with no common superscript differ significantly (p < 0.05). 
1Blood samples were taken at 24 h post-challenge. The cellular identification of 200 
leukocytes was performed based on morphological characteristics as described by Lucas 
and Jamroz (1961), and the relative percentage of each identified cell type reported. 
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Figure 3.1. Control birds vs. treated birds (5 mg CSF-I2, days -1 and 0).  
Birds were injected with 30 cfu of Pasteurella multocida on day 0. Control (open bar) 
and CSF-I2 treated (hatched bar) received either a placebo of physiological saline or 5 
mg of CSF-I2 on days -1 and 0, respectively.  Mortality was monitored daily for one 
week. Each bar represents the average, cumulative mortality per cage (n = 3) of ten birds 
with its associated standard experimental error.  Different letters (a, b) designate 
differences (p < 0.05). 
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Figure 3.2. Control birds vs. treated birds (10 mg CSF-I2, days -1 and 0).  
Birds were injected with 18 cfu of Pasteurella multocida on day 0. Control (open bar) 
and CSF-I2 treated (hatched bar) received either a placebo of physiological saline or 10 
mg of CSF-I2 on days -1 and 0, respectively.  Mortality was monitored daily for one 
week. Each bar represents the average, cumulative mortality per cage (n = 5) of six birds 
with its associated standard experimental error.  Different letters (a, b) designate 
differences (p < 0.05). 
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Figure 3.3. Control birds vs. treated birds (10 mg CSF-I2, days -1, 0, 1).  
Birds were injected with 28 cfu of Pasteurella multocida on day 0. Control (open bar) 
and CSF-I2 treated (hatched bar) received either a placebo of physiological saline or 
10 mg of CSF-I2 on days -1, 0, and 1, respectively.  Mortality was monitored daily for 
one week. Each bar represents the average, cumulative mortality per cage (n = 5) of 
twelve birds with its associated standard experimental error. Different letters (a, b) 
designate differences (p < 0.05). 
4 2 
Fi g ur e 3. 4.  C o m p aris o n of diff er e nt d os a g e r e gi m e ns.  
T h e p er c e nt a ge m ort alit y of  C S F-I 2 tre at e d bir d s w a s s u btr a ct e d fr o m it s a s s oci at e d 
c o ntr ol gr o u p s m ort alit y f or e a c h tr e at m e nt r e gi m e:  5 m g C S F-I 2 (i. m., d a y - 1 a n d 0), 
( ); 1 0 m g C S F-I 2 (i. m., d a y - 1 a n d 0), ( ); a n d 1 0 m g C S F-I 2 (i. m., d a y - 1, 0, 
a n d 1), ( ). 
CHAPTER IV 
REDUCING MORTALITY IN SALMONELLA TYPHIMURIUM INFECTED 
MICE WITH A TRI-PEPTIDIC SERUM FRACTION 
INTRODUCTION 
The biotechnology revolution has ushered in the age of molecular medicine and 
created entirely new rationale for the diagnosis, treatment, and prevention of disease. 
Our understanding of the fundamental biochemical processes underlying cell function 
grows daily. Consequently, there are burgeoning opportunities for novel strategies for 
the diagnosis and treatment of disease processes.  In no other area of research is this 
more evident, and potentially more beneficial, than in the development of new medicinal 
agents or therapeutic regimes. 
Bio-active peptides have been found to possess antiviral, antibacterial, antifungal, 
and wound healing properties (Sanglier et al., 1993; Mizuno et al., 1995; Hancock, 
1999). A decameric peptide has been shown to impede the growth and spread of 
established tumors (Folkman, 1999). Cationic peptides help defend against the constant 
assault of moderate numbers of bacteria. Each natural peptide has a broad but 
incomplete spectrum of activity. The host compensates for this by producing an array of 




s y n er g y wit h o n e a n ot h er.  A n i n di vi d u al m a y pr o d u c e d o z e ns of diff er e nt p e pti d es, a n d 
m or e t h a n 5 0 0 n at ur al c ati o ni c p e pti d es h a v e b e e n d es cri b e d.  It is b eli e v e d t h at t h es e 
d ef e n s e   p e pti d e s are m or e g e n er al i n a cti o n t h a n a nti b o di e s, a n d a s s u c h, h a ve a 
br o a d er r a n g e of a cti vit y ( H a n c o c k, 1 9 9 9).  T h es e p e pti d es h a v e l o w t o xi cit y t o m ost 
m a m m ali a n c ell s a n d ar e t h er ef ore c a n di d at e s f or d e v el o p m e nt a s pr o p h yl a cti c a g e nt s 
( M al o y a n d K ari, 1 9 9 5). 
W e r e c e ntl y fr a cti o n at e d c a pri n e s er u m i n or d er t o is ol at e its c o m pl e m e nt of 
p e pti d e s.  W e p arti all y p urifi e d a s a m pl e w hi c h w h e n a n al y z e d b y hi g h p erf or m a n c e si z e 
e x cl u si o n c hr o m at o gr a p h y re v e al e d t h e pr e s e n c e of t hr e e p e pti de s wit h m ol e c ul ar 
w ei g ht s b el o w 8 k D.  T hi s fr a cti o n h a d n o ba ct eri ci d al a cti vit y b ut w h e n a d mi ni st er e d 
i m pr o v e d si g nifi c a ntl y t h e s ur vi val of c hi c k e ns i nf e ct e d wit h P ast e ur ell a m ult o ci d a 
( Will ef or d et al. , 2 0 0 0).  T his tri- p e pti di c is ol at e is i d e ntifi e d b el o w as C S F-I 2, or 
C a pri n e s er u m fr a cti o n - i m m u n o m o d ul at or 2. 
I n t hi s st u d y w e d e v el o p a m o d el t o h el p c h ar a ct eri z e t h e s a m pl e s pr o p h yla cti c 
b e n efit i n mic e.  Si x- we e k ol d, f e m al e S wi s s W e b st er mi c e w er e i nj ect e d 
i ntr a p erit o n e all y (i. p.) wit h S al m o n ell a t y p hi m uri u m  o n d a y 0 ( ~ 5. 0 0 x 1 03 
b a ct eri a/ m o us e ), eff e cti v e l y e st a blis h i n g a n  L D 8 0  b y d a y 7 t o d a y 8 p ost- c h all e n g e. 
S u b c ut a n e o us i nj e cti o ns of C S F-I 2 w er e pr o v i d e d t o t h e   tr e at e d mi c e i nf e ct e d wit h S. 
t y p hi m uri u m.  M ort alit y w as c o m p ar e d b et w e e n mi c e gi v e n n o C S F-I 2 a n d t h os e 
pr o vi d e d C S F-I 2 at v ari o u s p eri o d s pri or t o i nf e cti o n.  St u di e s w er e p erf or m e d i n t hi s 
m a n n er t o d eter mi n e t h e o pti m al ti m e of C S F-I 2 a d mi nistr ati o n a n d a C S F-I 2 d os e 
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response profile.  Murine macrophage studies were also undertaken to determine whether 
administration of CSF-I2 can directly stimulate macrophage activity. 
MATERIALS AND METHODS 
Animal Care 
Four-week old, female Swiss Webster mice were purchased from Charles River 
Laboratories (Wilmington, MA).  The mice were acclimated for two weeks, during which 
time they were fed a standard maintenance diet, Laboratory Rodent Diet 5001 (PMI 
Feeds, Inc.), and watered ad libitum. Mice were group-housed (5 mice per cage) in 
plastic boxes bedded with wood shavings and were transferred to an isolation room 
immediately after inoculation with S. typhimurium. The isolation room was maintained 
at 20oC in a controlled negative pressure environment on a 12 h lighting cycle.  Animal 
care and use were in accordance with the policies of the Institutional Animal Care and 
Use Committee of Mississippi State University. 
Bacteria 
Salmonella typhimurium (ATCC 14028) was used as the challenge organism after 
passaging three times through a murine host with subsequent isolation and stored in 
phosphate buffered saline with 10% glycerol at -80oC. This isolate was supplied from a 
stock culture from the Department of Biological Sciences (Mississippi State University) 
where it is maintained as a reference organism.  Culture rehydration and cryoprotective 
maintenance conditions have been described previously (Darnell et al., 1987). 
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Preparation of Caprine serum fraction - immunomodulator 2 (CSF-I2) 
CSF-I2 was fractionated from goat serum by collecting the material which flowed 
through a dialysis membrane (Spectrum Laboratories, Inc.) with a molecular weight cut-
off of 6-8 kDa. This low molecular weight material was lyophilized to a powder and 
stored at -70oC until reconstituted with water for use. Powdered CSF-I2 contained 37.5% 
protein based upon nitrogen content. 
Experimental Design 
Mice comprising the control and treated populations were injected i.p. with 
0.1 ml of Salmonella typhimurium (~5.00 x 103 bacteria/mouse) on day 0.  Unless stated 
otherwise, treated mice were given a 0.25 ml subcutaneous injection of CSF-I2 (5 mg) at 
the time designated by the experimental protocol, while control mice received a placebo 
of physiological saline.  Negative control mice were sham handled in a similar manner to 
the control and treated populations to evaluate the influence of non-experimental 
parameters on mortality.  To obtain statistical significance, mice were housed five per 
cage and a minimum of five cages were used per treatment group.  Mice were monitored 
three times daily and mortality recorded until 80% of the control mice died. 
Effect of Heat Treatment on CSF-I2
CSF-I2 (20 mg/ml) was brought to 85oC for 30 min and 5 mg doses were 
administered to mice according to the experimental design described above. 
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Limbulus amebocyte Lysate (LAL) Endotoxin Quantitation Assay 
The standardized endotoxic activity for two independent preparations of CSF-I2 
was determined by Associates of Cape Cod (Woods Hole, MA) using an LAL gel clot 
assay. The threshold sensitivity of the reaction was 0.03 endotoxic unit (EU) per ml. 
Cell Culture
RAW 264.7 cells (murine alveolar macrophage line) were obtained from 
American Tissue Culture Collection (ATCC TIB-71, Manassas, VA) .  Cells were 
cultured in a complete medium [Dulbecco s Modified Eagle s Medium (DMEM) 
adjusted to contain 4.5 g/L glucose, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 
4mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml 
amphotericin with a final concentration of 10% fetal bovine serum] specified by ATCC. 
Cells were maintained at 37oC in a 5% CO2 humidified incubator. 
Nitrite Quantitation 
A Griess Reagent Kit (Molecular Probes, Eugene, OR) was used to determine 
nitrite (NO2) levels produced by stimulated and non-stimulated macrophages. Cells were 
plated at 1 x 105 cells/cm2 in 24-well culture plates and allowed to adhere for four hours. 
Medium was then removed and replaced with complete medium (control wells), or 
complete medium supplemented with CSF-I2 (0.1, 1, or 10 mg/ml) or 50 g/ml 
lipopolysaccharide (LPS serotype O127:B8; Sigma, St. Louis, MO) for 72 h (n=4). 
Separate plates were used for the three time points (i.e., 24, 48, and 72 h). Supernatant 
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(150 l) was removed at the designated time and mixed with 20 l Griess reagent 
(0.1% naphthylethylene diamine dihydrochloride, 1% sulfanilamide, 3% H3PO4) and 
130 l ddH2O in a 96 well tissue culture plate.  The microplate was then incubated at 
37oC for 30 min and absorbance read at 548 nm on a Quant Plate Reader (Biotek 
Instruments, Winooski, VT), with a standard curve generated with sodium nitrite. 
Protein Determination 
Protein determinations of adherent macrophages were made in order to 
standardize nitrite production.  Supernatant was removed for nitrite analysis and the well 
was washed with sterile PBS. Adherent cells were lysed by adding 1 ml 0.3M NaOH and 
incubating for 30 min at room temperature. A Bradford assay for microplates (Bio-Rad, 
Hercules, CA) was run in triplicate as per kit instructions. Briefly, 20 l of the lysis 
supernatant and 200 l Bradford reagent were added to a well and incubated at room 
temperature for 30 min.  Absorbance was then measured on a Quant Plate Reader at 
595 nm. A standard curve was prepared from bovine serum albumin (BSA) in 
0.3M NaOH. 
Statistical Analysis 
All experiments were arranged in a completely randomized design.  Data 
demonstrating cumulative mortality were analyzed separately for each time point using 
one way analysis of variance (ANOVA) with the general linear models procedure (PROC 
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G L M) a n d t h e m e a ns s e p ar at e d b y F is h er s pr ot e ct e d L S D pr o c e d ur e ( S A S I nstit ut e I n c., 
1 9 9 7).  A p val u e l e s s t h a n 0. 0 5 w a s n e c e s s ar y t o b e c o n si d er e d si g nifi c a nt. 
R E S U L T S 
L A L E n d ot o xi n Q u a ntit ati o n Ass a y 
T w o s e p ar at e pr e p ar ati o n s of C S F-I 2 w er e a n al yz e d f or e n d ot o xi c a cti vit y.  E a c h 
pr e p a r ati o n h a d e q ui v al e nt e n d ot o x i n l e v els of 0. 8 E U/ m g. 
Eff e ct of V ari o us Tr e at m e nt R e gi m e ns o n t h e R esist a n c e of Mi c e t o S. t y p hi m uri u m 
T h e eff e ct of v ar yi n g t h e ti mi n g, d os a g e, a n d fr e q u e n c y of C S F-I 2 pr etr e at m e nt 
o n t h e s ur vi v al of mi c e t o a p ot e nti all y l et h al c h all e n g e wit h S. t y p hi m uri u m  w a s 
i n v esti g at e d i n or d er t o d et er mi n e t h e o pti m al a d mi nistr ati o n f or C S F-I 2.  A si n gl e d os e 
of C S F-I 2 w a s a d mi ni st er e d at v ari o u s ti me s pri or t o c h all e n ge t o a s s e s s p er si st e n c e of it s 
p ositi v e eff e cts a n d t o as c ert ai n t h e o pti m al ti m e of its a d mi nistr ati o n wit h r e g ar d t o t h e 
S.  t y p hi m uri u m c h all e n g e m o d el.  C S F-I 2 w as a d mi nist er e d o n eit h er d a y - 4, - 2, - 1, or 
c oi n ci d e nt wit h t h e c h all e n g e o n d a y 0 ( Fi g ur e 4. 1).  Fo ur d a ys w er e u s u all y re q uir e d 
b ef or e d e at hs w er e o b ser v e d i n c o ntr ol p o p ul ati o n s of f e m al e S wi ss W e b ster mi c e 
c h all e n g e d wit h S. t y p hi m uri u m  ( ~ 5 x 1 03  b a ct eri a/ m o u s e).  A r a pi d ri se i n d e at h e n s u e d 
wit h a p pr o xi m at e l y 8 0  % m o rt a lit y o c c u rri n g 8 d a ys p ost- c h all e n g e .  Mi c e tr e at e d wit h 
C S F-I 2 f o ur d a ys pri or t o c h all e n g e s h o w e d n o si g nifi c a nt diff er e n c e fr o m t h e c o ntr ol. 
Pr o p h yl a cti c b e n efit, h o w e v er, w as o bs er v e d if C S F-I 2 w as gi ve n o n eit h er d a y - 2 or 0. 
B y d a y 8 t h e c o ntr ol p o p ul ati o n r e a c h e d 8 0 % m ort alit y, w hil e gr o u ps  t h at r e c ei v e d 
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CSF-I2 on either day -2 or 0 had percent mortalities of 60 and 54, respectively.  Mice 
treated one day prior to challenge had the least number of deaths.  Only 32% of this 
treated group was dead by 8 days post-challenge.  Beginning with day 5 post-challenge 
(when mortality was established in this control population) there was a statistically 
significant difference between the control group and each of the day -2, -1, and 0 
CSF-I2 treated groups.  The day -1 treatment group also had significantly lower mortality 
than the day 0 and day -2 CSF-I2 populations as exemplified by the day 8 p values of 
p = 0.0193 and p = 0.0014, respectively. 
A dose response study was performed in order to determine the optimal amount 
of CSF-I2 to administer for prevention of mortality (Figure 4.2).  CSF-I2 was prepared so 
that a subcutaneous injection would deliver either 0.1, 5, 15, or 20 mg CSF-I2.  All 
injections of CSF-I2 were given on day -1, as this was shown by the time course study to 
produce the greatest prophylactic benefit. On day 7, all doses were significantly different 
(p < 0.05) from the control mice except for the 0.1 mg CSF-I2 dosage.  Eighty three 
percent of the control population died by day 7, while with respect to increasing amounts 
of CSF-I2, 73.3, 33.3, 13.3, and 13.3% had died in these treated groups. 
Onset of mortality typically occurred 4 days post-challenge.  It was of interest to 
determine whether survival could be improved with supplemental administrations of 
CSF-I2.  Control mice were compared to treated groups which received CSF-I2 on day 
-1, on days -1 and 1, and on days -1 and 2 (Figure 4.3).  All treated groups had 
significantly fewer deaths than the control population between days 5 and 8.  There was 
51 
no significant difference in prophylactic benefit however between the populations which 
received either a single or multiple administrations of CSF-I2. 
Effect of Heat Treatment on CSF-I2 
When CSF-I2 was incubated at 85oC for 30 min the material no longer provided 
prophylactic benefit.  The mortality profile presented in the murine population treated 
with heated CSF-I2 (5 mg) was indistinguishable from the control population. 
Macrophage Nitrite Production 
The macrophages were stimulated by LPS to produce a significant increase in 
nitrite production over the control cells by day 2 (p < 0.0001).  CSF-I2 did not stimulate 
macrophage activity (as detected by nitrite production) when tested up to a concentration 
of 10 mg/ml (Figure 4.4).  Neither cytotoxic nor proliferative effects were observed due 
to the administration of CSF-I2. 
DISCUSSION 
Agents which retard pathogenesis may enable a host to mount a successful 
defense to challenges of the immune system.  These agents can provide specific 
protection (i.e., in the form of antibodies) or be general in nature and enhance overall 
immunocompetence. Cytokines and cationic peptides are two such classes of non-
specific defense agents.  We were able to isolate a mixture of three peptides which have 
an estimated molecular mass of approximately 5 kDa, as determined by size exclusion 
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chromatography (data not shown), from caprine serum which when administered to mice 
challenged with S. typhimurium significantly reduced ensuing mortality. The 
prophylactic benefit was issued in a dose dependent manner with a maximal effect 
garnered when approximately 15 mg CSF-I2 was administered.  Benefit appears to derive 
from CSF-I2's proteinaceous components in light of the observation that all benefit is lost 
upon incubation at 85oC, a procedure known to denature protein.  Support for this 
conclusion was derived from the observation that when CSF-I2 was digested overnight 
with the proteases Bromelain and Proteinase K, loss of therapeutic benefit was observed. 
CSF-I2 showed no bactericidal activity when surveyed against a battery of both 
gram-positive and gram-negative bacteria (Willeford et al., 2000) and did not contain a 
level of endotoxin sufficient to promote a pyrogenic response.  However, its 
administration is known to retard bacterial pathogenesis in chickens (Willeford et al., 
2000) and mice with the greatest survival observed when given approximately 24 hr 
before challenge. Significant benefit was observed when CSF-I2 was given at the time of 
challenge or two days before challenge but no benefit was observed when administered 
four days before a severe challenge. 
Clonal and non-clonal immunity can be found in serum in the form of 
immunoglobins, collectins, cytokines, chemokines, and cationic peptides (Janeway and 
Travers, 1997). Isolation of CSF-I2 effectively excludes globulins ( 180 kDa), 
collectins (a collection of multimeric proteins with a subunit molecular mass of 
approximately 50 kDa), and cytokines (~10-80 kDa) (Tizard, 1996; Nair et al., 2000). 
Chemokines (~8 kDa) function mainly as chemoattractants for phagocytic cells, 
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recruiting monocytes and neutrophils from the blood to sites of infection (Janeway and 
Travers, 1997).  Molecular mass estimates point more favorably towards a cationic 
peptide, some of which have a mass as low as 2 kDa. Cationic peptides have been found 
to have diverse physiological roles in vivo (Sanglier et al., 1993; Mizuno et al., 1995; 
Hancock, 1999), but are primarily associated with bactericidal activity with an MIC in 
the range of 1-100 g/ml (Martin et al., 1995; Hancock, 1997). CSF-I2 at concentrations 
over 2,500 times the upper MIC range recognized for cationic peptides produced no 
bactericidal activity against Salmonella typhimurium (Willeford et al., 2000). 
Preliminary sequence data shows, however, a significant presence of lysine and arginine, 
which is consistent with the nature of cationic peptides.  The bio-active peptide(s) in 
CSF-I2 may initiate an atypical or unclassified response for a cationic peptide. 
It is unclear whether administration of CSF-I2 affects the ability of the host to kill 
the bacteria, control their subsequent rate of growth, or both.  However, CSF-I2 
influences in a positive way the ability of the host to withstand and survive a challenge of 
an infectious agent. 
Studies are being pursued in order to elucidate CSF-I2's mechanism of action. 
While CSF-I2 does not appear to work through directly stimulating macrophages, it 
remains possible that CSF-I2 is causing an indirect stimulation through the production of 
macrophage activating effector molecules such as IFN or TNF. 
The search for agents which potentiate the immune response is a driving force in 
drug research. Use of immune regulating or immune modulating molecules should 
induce a state of general hyperactivity of the immune system which should precipitate 
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and/or enhance the prophylactic response to immune challenges such as pathogenic 
infection. If such a non-specific immune response could be initiated at will, it could be 
utilized to either act alone or in conjunction with conventional treatments directed 
towards etiological agents and the progression of a diseased state.  CSF-I2 appears to 
possess an immunomodulatory activity. Further investigation is required to determine 
the nature of the immune-regulatory compound and elucidate its mode of action. 
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Figure 4.1. Optimal Time of CSF-I2 Administration (Time Course Profile).  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 (+), 
while treated mice received both S. typhimurium on day 0 and a 0.25 ml subcutaneous 
injection of CSF-I2 (5 mg) either on day -4 ( ), day -2 ( ), day -1 ( ), day 0 ( ). 
Each data point represents the average daily mortality (n = 5) with its associated SEM 
per cage of 5 mice. 
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Figure 4.2. CSF-I2 Dose Response Profile.  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 (+), 
while treated mice received both S. typhimurium on day 0 and a subcutaneous injection 
of either 20.0 mg ( ), 15.0 mg ( ), 5.0 mg ( ), or 0.1 mg ( ) CSF-I2.  Each data point 
represents the average daily mortality (n = 6) with its associated SEM per cage of 5 mice. 
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Figure 4.3. Effect of Multiple Administrations of CSF-I2.  
Control mice were administered 0.1 ml (~5 x 103 cfu) of S. typhimurium i.p. on day 0 (+), 
while treated mice received both S. typhimurium on day 0 and a 0.25 ml subcutaneous 
injection of CSF-I2 (5 mg) on either day -1 ( ), days -1 and 1 ( ), or on days -1 and 2 
( ). Each data point represents the average daily mortality (n = 6) with its associated 
SEM per cage of 5 mice. 
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Figure 4.4. Macrophage nitrite determination. 
Macrophages were plated at 1 x 105 cells/ml in 24 well tissue culture plates. After four 
hours, medium was removed and replaced with complete medium ( ) or complete 
medium supplemented with CSF-I2 (0.1, ; 1, ; and 10 mg/ml, ) or 50 g/ml LPS 
( ). Nitrite and protein were assessed at 24, 48, and 72 h.  The results are expressed as 
the mean M nitrite produced/mg adherent protein with its associated SEM from four 
wells. 
           
CHAPTER V 
IMPROVED SURVIVAL OF CANINES WITH PARVOVIRUS WHEN 
TREATED WITH A TRI-PEPTIDIC SERUM FRACTION 
INTRODUCTION
Canine parvovirus (CPV) was first identified in Greece in 1974 and by 1978 had 
spread throughout Europe and the United States. Cases were diagnosed worldwide by 
1979 (Pollock and Coyne, 1993). Infection is acquired by ingestion of infective virus and 
may spread quickly from dog to dog. The virus requires rapidly dividing cells for its 
replication (Dunn et al., 1995a), thus targeting the intestinal tract, lymphoid tissues, and 
bone marrow, with marked plasma viremia observed three to five days after infection and 
enteric distress shortly thereafter (Pollock and Coyne, 1993). Dogs from 1-6 months of 
age should be considered at risk of CPV infection, but the most severe, often fatal, 
incidence of CPV occurs in puppies less than three months of age (Tilley and Smith, 
1997). 
CPV is a small, non-enveloped single-stranded DNA-containing virus (Parrish, 
1999) that is genetically and antigenically closely related to two other parvoviruses, 
feline panleukopenia virus and mink enteritis virus (Parrish et al., 1982).  Vaccines have 
been developed which provide long-term, if not complete, immunity.  However, such 
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protective measures are effective only if given when maternally acquired CPV antibodies 
have declined to the point where the puppy has become susceptible to infection, and thus 
responsive to vaccination. This period typically extends from 4-16 weeks of age.  If the 
disease is acquired during this period of susceptibility, a key determinant in the animal s 
survival depends on its ability to limit the magnitude and duration of viremia.  Dogs 
which survive the acute stage of infection usually recover fully and possess lasting 
immunity (Pollock and Coyne, 1993). 
Supportive care, the cornerstone of CPV therapy, provides time for the host to 
mount an effective immune response.  Supportive therapy consists mainly of fluid 
replacement, restoration of acid/base balance, antiemetics, antibiotic treatment to prevent 
secondary bacterial infection, and restrictive diet (Pollock and Coyne, 1993; Dunn et al., 
1995b). Other than supportive therapy, only recombinant feline interferon-  -
INTERCAT (Toray Industries, Tokyo, Japan) has been shown to be effective for CPV 
infection.  It s mode of action is thought to derive primarily from interferon s antiviral 
activity, but INTERCAT may also activate immunological responses (Minagawa et al., 
1999). 
Discovering agents which potentiate the immune response is a driving force in 
drug research. Cytokines and cationic peptides are two classes of compounds found in 
serum which have shown promise in this area of research.  Bio-active peptides have been 
observed to inhibit the growth and spread of established tumors, promote antiviral, 
antibacterial, antifungal, and even wound healing properties (Sanglier et al., 1993; 
Mizuno et al., 1995; Folkman, 1999; Hancock, 1999).  It is believed that these  defense 
61 
peptides are more general in their actions than antibodies, and as such, have a broader 
range of activity (Hancock, 1999). 
Caprine serum fraction - immunomodulator 2 (CSF-I2) was isolated from serum 
and clinically evaluated for therapeutic benefit. CSF-I2 had no bactericidal activity, but 
when administered improved the survival of chickens infected with Pasteurella 
multocida (Willeford et al., 2000) and mice infected with Salmonella typhimurium. 
There have been no studies, however, to determine whether CSF-I2 provides therapeutic 
benefit against a viral challenge.  The purpose of this study was to determine the efficacy 
of CSF-I2 as a supplement to conventional supportive therapy for CPV infection.  
MATERIALS AND METHODS 
Selection Criteria 
Animals between eight and twelve weeks of age were included in the study if 
diagnosed with canine parvovirus by fecal ELISA examination.  Animals were excluded 
from the study if they were unconscious or died within 8 h of admission. 
Supportive Therapy 
Treatment at the veterinary clinic (St. Paul, MN) depended upon the animal s 
presenting condition and included fluid replacement, antiemetics, anti-endotoxic agents, 
and/or antibiotics for treatment of possible secondary infections. 
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Experimental Design 
All dogs diagnosed for CPV through a fecal ELISA examination (IDEXX, 
Westbrook, ME) were immediately placed on supportive therapy.  Upon owner consent, 
a subpopulation of this group was administered CSF-I2 therapy (Willeford et al., 2000). 
This consisted of a single intramuscular (i.m.) injection of 0.5 ml CSF-I2 (3 mg/ml). 
After three days, the dogs were given a second injection of CSF-I2 and assessed for their 
response to initial therapy. An additional follow-up was conducted one week later. 
Cell Culture and Medium 
Canine fibroblast A-72 cells from the American Type Culture Collection (ATCC 
CRL-1542) were cultured in Eagles minimal essential medium supplemented with 5-10% 
(v/v) heat inactivated Fetal Bovine Serum, 100 units/ml penicillin, 10 g/ml gentamicin, 
and 2.5 g/ml fungizone. Cultures were maintained as monolayers in tissue culture 
labware at 36-38oC in a humidified atmosphere of 5-7% CO2. 
Canine Parvovirus 
Canine parvovirus (VR-2017) was originally obtained from the ATCC and 
cryogenically stored at -70oC. The virus was propagated in A-72 cells in disposable 
tissue culture labware as described above. 
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Virucidal/Antiviral assays 
The virucidal and antiviral interactions between CSF-I2 and CPV were assessed 
by ViroMed Biosafety Laboratories (St. Paul, MN).  In the virucidal assay, CPV was 
incubated with dilutions of 100 - 0.001 g/ml CSF-I2 for four hours, and then added to 
wells containing canine fibroblast A-72 cells (test wells).  Wells were also established to 
represent a cell control (cells which are neither exposed to CPV or CSF-I2) and virus 
control (cells which are exposed to CPV following incubation with culture medium). 
After incubation of the cells for 12 days, the supernatants from the cell control, virus 
control and CSF-I2 treated wells were assayed for virucidal activity using a 
hemagglutination assay.  In order to determine whether CSF-I2 was directly cytotoxic to 
the canine fibroblasts, cells were plated and exposed to CSF-I2. After incubating for 12 
days, the wells were assessed for cellular proliferation using a Microculture Tetrazolium 
Assay (Delhaes et al., 1999). 
In the antiviral assay, canine fibroblast A-72 cells were exposed to CPV for 2 h 
and then either CSF-I2 (up to 100 g/ml) or culture medium was added to establish the 
treated and virus control samples.  Wells plated with cells that had neither been exposed 
to CPV nor CSF-I2 were used to establish a cell control well.  Cells were incubated for 
10 days and their supernatants assayed for viral infectivity using a hemagglutination 
assay. 
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RESULTS AND DISCUSSION 
A field study incorporating data from 33 clinics in Japan showed that canines 
which received supportive therapy for CPV (n = 21) experienced a near 60% mortality 
(Minagawa et al., 1999). All data used in our study were obtained from a veterinary 
clinic located in St. Paul. MN. When canines were diagnosed with CPV and 
administered supportive therapy at this site, the mortality was 45% (n = 150). 
A total of 74 CPV cases diagnosed at this center also received supplemental 
CSF-I2 therapy.  Fifty-six dogs, confirmed to have contracted CPV based upon fecal 
ELISA examination, were placed immediately on supportive therapy and administered 
CSF-I2.  Six deaths were reported, resulting in a mortality of 10.7% (6/56), well below 
the average for dogs treated solely with supportive therapy at this site and that reported 
by Minagawa et al. (1999). Fourteen dogs were diagnosed with CPV based upon their 
presentation of clinical symptoms.  With supportive therapy supplemented by CSF-I2 
there was only one recorded death. Littermates to CPV patients may test negative for 
CPV and then abruptly show CPV symptomology.  Four CPV littermates were treated 
with CSF-I2, and no deaths were recorded.  Of the 74 cumulative CPV cases where 
conventional treatment was supplemented by administration of CSF-I2, there were 7 
deaths; constituting a collective mortality of 9.5% (Fig. 5.1). When treatment 
incorporated the use of CSF-I2, patients received substantial benefit, as evidenced by 
their increased survival. 
INTERCAT, an approved veterinary antiviral agent, has been shown to improve 
upon conventional CPV therapy. A total of 93 CPV dogs from thirty-three veterinary 
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clinics in Japan were administered INTERCAT once a day for 3 consecutive days at a 
dose of 1 or 2.5 million units/kg. Mortality dropped from 61.9% (13/21) in the control 
group to 19.4% (14/72) when INTERCAT was utilized (Minagawa et al., 1999). It is 
clear that conventional CPV therapy can be improved upon, as both CSF-I2 and 
INTERCAT were able to lower the incidence of death by approximately forty percent.  It 
would be of interest to evaluate whether these adjunct therapies are able to act in concert 
to further improve survivability. 
CSF-I2 may also impart antiviral activity.  Therefore it was necessary to 
determine whether CSF-I2 has the ability to directly kill CPV (i.e., possesses in vitro 
virucidal activity). In order to assess CSF-I2's virucidal activity to CPV it was necessary 
to first establish whether the viability of the A-72 host cell line was impaired by the 
presence of CSF-I2. Cell proliferation was not affected adversely when exposed to 
CSF-I2 at concentrations from 0.001 - 100 g/ml CSF-I2 (Figure 5.2).  CSF-I2 was not 
virucidal to CPV as infectivity and proliferation were not affected by prior exposure to 
CSF-I2.   
The in vivo antiviral activity of CSF-I2 was also assessed in this cell line.  There 
was no evidence that CSF-I2 promoted antiviral activity within the host cell.  While 
canine fibroblast A-72 cells are used to support growth of CPV, they were not developed 
to be immunocompetent. Isolated cell lines often lack the ability to mount a full immune 
response. 
It is clear from the data provided that CSF-I2 promotes resistance to CPV 
infection without acting as a virucidal agent.  The mechanism by which it accomplishes 
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t his t as k r e m ai ns t o b e el u ci d at e d.  It h as als o b e e n r e p ort e d t h at w hil e C S F-I 2 h as n o 
b a ct eri ci d al a cti vit y it e n a bl e s a re ci pi e nt t o bett er wit h st a n d a p ot e nti all y l et h al b a ct eri al 
c h all e n g e ( Will ef or d et al. , 2 0 0 0).  C S F-I 2 a p p e ars t o pr o vi d e t h er a p e uti c b e n efits a g ai nst 
b ot h mi cr o bi al a n d viral c h all e n g e s.  F ut ur e st u di e s ar e r e q uir e d t o d et er mi n e t h e f ull 
e xt e nt of C S F-I 2 s bi o a cti vit y a n d m o d e of a cti o n. 
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Figure 5.1. Improving conventional CPV therapy by administration of CSF-I2 or the 
antiviral agent INTERCAT. 
The open bar represents the mortality present in the control group of dogs which were 
treated for CPV by supportive therapy while the hatched bar shows the mortality when 
conventional therapy was supplemented by administration of CSF-I2 (see Materials and 
Methods for details) or INTERCAT (Minagawa et al., 1999). 
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Figure 5.2. Cytotoxicity Assay.  
Canine fibroblast A-72 cells were plated and exposed to dilutions of CSF-I2 from 100 -
0.001 g/ml for four hours. The cells were then incubated for 12 days, and a 
Microculture Tetrazolium Assay was used to assess cellular proliferation.  Each point 
represents the average of the replications (n=3) for each concentration of CSF-I2 tested 
relative to the average proliferation of cells not exposed to CSF-I2 with its associated 
standard experimental error. 
C H A P T E R VI 
I S O L A TI O N O F A N I M M U N O M O D U L A T O R Y C A P RI N E F A C T O R 
I N T R O D U C T I O N 
St u di es c o n d u ct e d i n o ur l a b or at or y r e v e al e d t h e pr es e n c e of a g o at s er u m f a ct or 
t h at si g nifi c a ntl y i m pr o v e d t h e o v er all s ur vi v al of a ni m al s e x p erie n ci n g p ot e nti all y l et h al 
p at h o g e ni c c h all e n g es ( Will ef or d et al. , 2 0 0 0; Will ef or d et al. , 2 0 0 1; H a m m et al. , 2 0 0 2). 
T h e p h ysi c al n at ur e of t his  f a ct or w as u n k n o w n; t h e si z e, c o m p ositi o n a n d m o d e of 
a cti o n w er e n ot el u ci d at e d. 
T h e cr u d e g o at s er u m is ol at e w as f o u n d t o p oss ess c ar b o h y dr at es, li pi ds a n d 
pr ot e i n a c e o us m at eri al.  All t h r e e o f t h e s e br o a d cl ass es of bi ol o gi c al c o m p o u n ds h a v e 
b e e n o b s er v e d t o pr o d u c e f u n cti o n al i m m u n o m o d ul at or s ( e. g., a c e m a n n a n, li pi d 
m o n o p h os p h or yl A, a n d c ati o ni c p e pti d es) ( H a d d e n, 1 9 9 3; A b b as a n d J a n e w a y, 2 0 0 0; 
H a m m et al. , 2 0 0 2).  B ef or e a p urifi c ati o n pr ot o c ol c o ul d b e d esi g n e d, it w as i m p ort a nt 
t o e st a bli s h a r eli a bl e a ss a y a n d i d e ntif y w hi c h cl a ss of bi ol o gi c al c o m p o u n d s ge n er at e d 
t h e bi ol o gi c al a cti vit y of i nt er est.  T o d at e, t h e o nl y pr o v e n ass a y d e n oti n g t h e f a ct or s 
bi o a cti vit y is d eri v e d fr o m a ni m al m o d el st u di es a n d s h o ul d b e c o nsi d er e d t h er ef or e 
r el ati v el y i ns e nsiti v e. 
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Upon conducting a thermal stability study it was observed that biological activity 
was lost when material was incubated at 85oC for 30 minutes or 100oC for 15 minutes. 
This result indicated that the factor was proteinaceous in nature.  This hypothesis was 
verified with the loss of bioactivity after proteolytic digestion.  
All subsequent studies involving purification centered around the hypothesis that 
the active agent(s) were proteinaceous.  Moreover, caution had to be exercised also to 
retain immunomodulatory activity, as it was the only marker for the factor s presence. 
Purification procedures were employed which permitted initially the large scale or bulk 
separation of serum components (e.g., proteins versus peptides). Analytical resolution 
was subsequently used to characterize the nature of the bulk-isolated material (e.g., 
molecular weight and amino acid analysis). Studies reported here reflect the progress of 
this effort. 
MATERIALS AND METHODS 
Protein Denaturation Studies 
Effluent obtained after equilibrium dialysis (6-8 kDa MWCO) was performed 
was concentrated to 20 mg/ml and either digested overnight with 0.36 units/ml bromelain 
and 2 mg/ml proteinase K at 4oC or incubated at either 85oC for 30 min or 100oC for 15 
min. After these treatments were performed, the bioactivity was assessed according to 




Molecular porous membrane tubing (Spectrum Laboratories, Inc) with a 
molecular weight cut off (MWCO) range of 12-14 kDa, 6-8 kDa, or 1 kDa was used to 
perform equilibrium dialysis.  Caprine serum (Colorado Serum Co.) was dialysed at 4oC 
against approximately ten volumes of double distilled deionized water for 24 hours. 
Material which flowed through the dialysis membrane (caprine serum fraction -
immunomodulator 2 or CSF-I2) was lyophilized (Lyph Lock 6, Labconco, Kansas City, 
MO) to a powder and stored at -70oC until reconstituted with water for use. 
Centrifugal Ultrafiltration
Ultrafiltration was conducted on CSF-I2 by using a centrifugal force of 5000 x g 
to drive material through an Amicon Centricon YM-30 (30 kDa MWCO), YM-10 (10 
kDa MWCO) or YM-3 (3 kDa MWCO) in accordance to manufacturer s instructions.  If 
the sample volume was greater than 10 ml an Amicon Centriprep YM-10 (Millipore 
Corp, MA) apparatus operated at 3000 x g was used. 
Size Exclusion Chromatography 
Size exclusion chromatography was performed with either a Superdex 200 HR 
10/30 (Pharmacia LKB Biotechnology, Uppsala, Sweden) or a TSK G2000 SWXL 
(Phenomenex, Torrance, CA, 300mm x 7.8mm). 
Twenty l aliquots of sample (i.e, caprine serum, CSF-I2, or TPI) were applied to 
a Superdex 200 HR 10/30 size exclusion column equilibrated in 10 mM sodium 
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phosphate (pH 7.1) and 150 mM NaCl.  The column was calibrated with BioRad gel 
filtration chromatography standards [thyroglobulin (670 kDa), IgG (158 kDa), ovalbumin 
(44 kDa), myoglobin (17 kDa) and Vitamin B12 (1.35 kDa)].  The operating system used 
was a Hewlett Packard 1100 HPLC operated at a flow rate of 1 ml/min and set to detect 
at 280 nm. 
Twenty-five l of TPI (10 mg/ml) or a mixture of reference proteins was applied 
to an analytical TSK G2000 SWXL size exclusion column equilibrated with 200mM 
potassium phosphate (pH 6.8) containing 15mM NaCl.  The column was calibrated with 
BioRad gel filtration chromatography standards. The system was operated at 0.5 ml/min, 
the eluate was monitored at 214nm, and 0.5 ml fractions were collected. This procedure 
was conducted by Commonwealth Biotechnologies, Inc. (Richmond, VA). 
SDS Gel Electrophoresis 
Electrophoresis in the presence of sodium dodecyl sulfate was performed 
according to the discontinuous system developed by Laemmli (1970) with a 
4% acrylamide stacking gel (pH 6.8) and a 15% acrylamide resolving gel (pH 8.8) 
utilizing a BioRad Mini-PROTEAN II electrophoresis unit.  Low MW standards obtained 
from BioRad [i.e., phosphorylase b (97.4 kDa), serum albumin (66 kDa), ovalbumin 
(45 kDa), carbonic anhydrase (31 kDa), trypsin inhibitor (21.5 kDa), and aprotinin 
(6.5 kDa)] were used as a molecular weight reference guide.  Proteins were visualized 
utilizing a BioRad silver stain (Hercules, CA) as per kit instructions. 
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Reverse Phase HPLC 
Reverse phase HPLC was performed with a C-18 HPLC column (Alltech 
Absorbosphere C-18 5U, 150mm x 4.6mm) equilibrated in 0.1% aqueous TFA 
(trifluoroacetic acid). The column (attached to a Waters 600 E HPLC) was washed with 
this buffer for 10 min (1 ml/min) and bound material eluted by establishing a binary 
gradient which linearly increased the secondary buffer (80% acetonitrile, 0.1% aqueous 
TFA) to 100% over a 20 min period. A 100 l aliquot of TPI in 0.1% TFA was applied 
to the column.  Sample elution was monitored at 220 nm with an Agilent 1100 Series 
diode array detector, and peak fractions were spectrophotometrically scanned from 
200-400nm. 
Amino Acid Analysis 
Aliqouts obtained from the peak fractions resolved by TSK G2000 SWXL size 
exclusion chromatography were dried and hydrolyzed by gas phase HCl for 20 h at 
110oC. Following hydrolysis, the samples were dried, suspended in 0.4M borate 
(pH 10.2) and derivatized. Primary amino acids were derivatized with ortho-
phthaladehyde and secondary amino acids were derivatized with 9-fluorenylmethoxy-
carbonyl. Derivatives were separated by reverse phase HPLC and detected by UV 
absorbance. Quantitation was done with the Aminoquant software (Agilent 
Technologies, Palo Alto, CA) calibrated with Agilent standards.  This procedure was 
conducted by Commonwealth Biotechnologies, Inc. (Richmond, VA). 
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RESULTS 
Size exclusion methodologies were used to fractionate caprine serum. Caprine 
serum was initially separated into large and small molecular weight components by 
subjecting it to equilibrium dialysis.  The small molecular weight material isolated when 
dialysis was conducted with molecular porous tubing possessing a MWCO of 12-14 kDa 
or 6-8 kDa (CSF-I2) was able to inhibit murine mortality resulting from salmonellosis. 
This ability was lost however if the MWCO of the dialysis tubing was reduced to1 kDa 
(Fig. 6.1). 
The thermostability of the bioactive small weight material was assessed by 
incubating it as an aqueous solution at 85 or 100oC. The resulting material lost 
bioactivity (Fig. 6.2), which was also destroyed if the aqueous solution was subjected to 
proteolytic degradation by proteinase K and bromelain (Fig. 6.3).  As a consequence of 
these observations, all subsequent studies employed methodologies consistent with the 
purification and detection of proteinaceous material. 
Size exclusion chromatography was performed on goat serum with a Superdex 
200 HR 10/30 column (Fig. 6.4a).  Three peaks were detected at an absorbance of 
280nm. The first peak (21.5 min) had an estimated molecular mass of approximately 
300 kDa and constituted less than 10% of the total integrated area. The other two peaks 
(23.9 min and 26.3 min) were estimated to have molecular weights of 149 and 68 kDa, 
and constituted 41 and 51% of the total integrated area, respectively. The majority of the 
protein present in the goat serum migrated in a manner consistent with immunoglobin 
and albumin when resolved by SDS gel electrophoresis (data not shown). 
75 
The bioactive low molecular weight material obtained after equilibrium dialysis 
(CSF-I2) was concentrated and resolved subsequently by a Superdex 200 HR 10/30 size 
exclusion chromatography system.  The relative area of the immunoglobin and albumin 
peaks were greatly reduced and two peaks with molecular weights of 4.9 and 1.7 kDa 
appeared (Fig 6.4b).  When this material was passaged through an Amicon Centriprep 
YM-10 ultrafiltration device (MWCO 10 kDa), the effluent (i.e., TPI) had no high MW 
components present; over 90% of the material eluted with a molecular mass of 5.8 kDa 
(Fig. 6.4c).  Bioactivity remained associated with the low molecular mass material (Fig. 
6.5). If the material was fractionated with an Amicon Centriprep YM-3 ultrafiltration 
device (MWCO 3,000), the effluent did not possess bioactivity (data not shown).  When 
TPI (the bioactive low molecular weight material) was resolved by SDS gel electro-
phoresis only one band with a MW of approximately 6.5 kDa was detected (Fig 6.6). 
TPI was lyophilized to a powder and forwarded to Commonwealth 
Biotechnologies, Inc for resolution by analytical size exclusion chromatography 
(TSK G2000 SWXL).  Material which had resolved as a single peak from a Superdex 
200 HR 10/30 column now generated three discernable peaks with estimated molecular 
weights of 4.2, 1.9, and 1.2 kDa (Fig. 6.7).  Peak fractions were combined following 
multiple analytical fractionations (n=16), concentrated by lyophilization, and tested for 
bioactivity. A total of 8.8, 22.4, and 35.3 g was obtained for fractions 25, 27, and 29, 
respectively. Each treated mouse (n=25) received the following: fraction 25 
(352 ng/mouse), fraction 27 (896 ng/mouse), and fraction 29 (1,412 ng/mouse).  Only 
fraction 27 appeared to induce (p = 0.1114) a reduction in mortality by day 8 (Fig. 6.8). 
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An analysis of the amino acid composition showed that this fraction was composed of 
nearly 26% arginine (Table 6.1). 
Previous attempts to purify preparatively the bioactive peptidic isolates present in 
TPI by C-18 reverse phase chromatography were unsuccessful (data not shown). 
Bioactivity was lost when TPI was exposed to the organic solvents used to resolve the 
peptides (i.e., 0.1% trifluoroacetic acid, 35% acetonitrile).  Analytical C-18 reverse phase 
chromatography confirmed however the presence of three peaks (Fig. 6.9), which when 
scanned from 200-400nm revealed a  characteristic peptide profile lacking aromaticity 
(Fig. 6.9 insert). 
DISCUSSION 
Clinical studies provided evidence for the existence of a goat serum factor that 
enabled animals to better withstand potentially lethal pathogenic challenges (Willeford 
et al., 2000; Willeford et al., 2001; Hamm et al., 2002). The physical nature of this 
factor was unknown. Immunoglobin, a major constituent of serum, had previously 
been shown to inhibit sepsis in postoperative patients (Duswald et al., 1980). Caprine 
immunoglobin was unable, however, to inhibit salmonellosis when initiated in 
accordance with the animal model developed for this study (Willeford et al., 2001). 
Lipids, carbohydrates, and proteinaceous material are all known to be present in serum. 
All three of these broad classes of biological compounds have been observed to produce 
functional immunomodulators (Hadden, 1993; Abbas and Janeway, 2000; Hamm et al., 
2002). The caprine serum factor was classified preliminarily as proteinaceous after a 
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t h er m al st a bilit y st u d y r e v e al e d t h at bi o a cti vit y c o ul d b e eli mi n ate d u p o n i n c u b ati o n at 
8 5 o C.  T hi s h yp ot h e si s w a s v erifi e d w h e n a l o s s of bi o a cti vit y w a s o b s er ve d aft er 
i m pl e m e nti n g pr ot e ol yti c di g esti o n as a n ass a y pr etr e at m e nt of t h e s er u m is ol at e. 
T o d at e, t h e o nl y pr o v e n ass a y d e n oti n g t h e f a ct or s bi o a cti vit y is d eri v e d fr o m 
a ni m al m o d el st u di es.  W hil e r eli a bl e, it m ust b e c o nsi d er e d i ns e nsiti v e d u e t o t h e 
n u m b er of a ni m als r e q uir e d t o g e n er at e o bs er v ati o n al si g nifi c a n c e. P urifi c ati o n 
pr o c e d ur es w er e e m pl o y e d w hi c h p er mitt e d i niti all y t h e l ar g e s c al e or b ul k s e p ar ati o n of 
s er u m c o m p o n e nts (i. e,  pr ot ei ns v ers us p e pti d es).  T his a p pr o a c h h el p e d e ns ur e 
s uffi ci e nt a v ail a bilit y of a s s a y m at eri al w hil e c h ar a ct eri zi n g t h e f a ct or b y it s br o a d 
is ol a ti o n cl as sifi c ati o n.  A s eri es of si z e e x cl u si o n p r o c e d ur es pr o d u c e d a bi o a cti v e 
s a m pl e t h at w hil e v oi d of pr ot ei ns ( e. g., i m m u n o gl o bi n a n d al b u mi n) s h o w e d t h e 
pr es e n c e of at l e ast t hr e e p e pti d es ( Fi g ur e 6. 7).  E a c h p e pti di c is ol at e w as ass a y e d f or 
bi o a cti vit y.  O nl y o n e of t h e s e p e pti d e s, fr a cti o n 2 7 ( Fi g. 6. 8), a p p e ar e d ( p = 0. 1 1 1 4) t o 
pr o vi d e a h e alt h b e n efit.  M ort alit y wa s l e s s e n e d b y a s m u c h a s 2 0 %.  It m a y b e p o s si bl e 
t o est a blis h gr e at er si g nifi c a n c e b y pr o vi di n g t h e mi c e wit h m or e of t h e p e pti d e is ol at e. 
T h e mi c e i n t his st u d y r e c ei v e d a p pr o xi m at el y 1  g of p e pti d e, a n d t his w as g e n er at e d b y 
c o m bi ni n g fr a cti o n s fr o m 1 6 siz e e x cl u si o n c hr o m at o gr a p h y i s ol ati o ns.  T hi s pr o vi d e s a n 
i n di c ati o n a s t o t h e r el ati ve a m o u nt of t hi s f a ct or i n s er u m.  F urt h er, t h e st a bilit y of t hi s 
f a ct or t hr o u g h o ut p urifi c ati o n r e m ai n s u n cl e ar.  It i s a c o m m o n oc c urr e n c e f or p e pti d e s 
t o b e c o m e u nst a bl e w h e n r e m o v e d fr o m t h eir p h ysi ol o gi c al mili e u - t h us, t h e m or e 
n a k e d t h e p e pti d e, t h e gr e at er t h e p ossi bilit y f or d e n at ur ati o n ( H arris, 1 9 8 9). 
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T h e bi o a cti ve p e pti d e( s) h a d a m ol e c ul ar w ei g ht b et w e e n 3 a n d 1 0 k D a, a s 
d et er mi n e d b y m ole c ul ar filtr ati o n d e vic e s.  W h e n S D S gel el e ctr o p h or e si s w a s u s e d t o 
r e s ol v e bi o a cti ve s a m pl e s t h e pr e s e n c e of a p e pti d e b a n d wit h a M W of a p pr o xi m at el y 
6. 5  k D a w as r e v e al e d ( Fi g. 6. 6).  Si z e e x cl usi o n c hr o m at o gr a p h y t h e n n arr o w e d t h e M W 
r a n g e t o 4- 6 k D a ( Fi g. 6. 7). 
It h as n ot b e e n d et er mi n e d w h et h er f u n cti o n al i m m u n o m o d ul ati o n r ests wit h o n e 
or m or e of t h e p e pti d es is ol at e d.  T hr e e f a ct ors li mit e d o ur a bilit y t o att a c k t his q u esti o n 
s u c c essf ull y, t h e l a c k of a s e nsiti v e bi o ass a y, t h e li mit e d a b u n d a n c e of t h e p e pti d e f a ct or, 
a n d t h e pr o b a bl e d e n at ur ati o n of t h e p e pti d e(s) of i nt er est u p o n p urifi c ati o n. It m a y b e 
p ossi bl e t o o bt ai n gr e at er a m o u nts of t h e bi o a cti v e p e pti d e (s) b y usi n g a pr e p a r ati v e si z e 
e x cl u si o n c ol u m n ( e. g., Bi o Gel P 2).  U p o n c o nfir mi n g t h e pre s e n c e of bi o a cti vit y, it m a y 
b e p o ssi bl e f or s e q u e n ci n g t o b e p erf o r m e d o n t h e  p e pti d es o f i nt e r est, a n d t h e n t hr o u g h 
d e n o v o  s y nt he si s a c q uir e e n o u g h p urifi e d mat eri al t o verif y bi o a cti vit y t hr o u g h a n 
est a blis h e d a ni m al m o d el. Ulti m at el y, it will b e ess e nti al t o el u ci d at e t h e f a ct or s 
s e q u e n c e. 
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Table 6.1. Amino acid analysis1. 
Amino acid Mole %
 Fraction 25 Fraction 27 Fraction 29                      
As(x) 13.49 7.53 10.96 
Gl(x) 9.36 6.31 9.00 
Ser 4.41 2.97 4.45 
His 2.49 1.01 1.33 
Gly 10.66 19.11 8.91 
Thr 5.24 4.10 4.84 
Ala 12.14 9.04 13.11 
Arg 5.05 25.83 6.58 
Tyr 3.18 1.78 2.94 
Cystine 0.00 0.00 0.46 
Val 6.54 3.86 5.95 
Met 2.03 1.54 1.84 
Trp NA2 NA NA 
Phe 3.48 2.15 3.17 
Ile 4.45 2.80 3.63 
Leu 7.97 4.94 7.38 
Lys 5.35 3.17 8.65 
Pro 4.16 3.86 6.80 
1Aliqouts obtained from the peak fractions resolved by TSK G2000 SWXL size exclusion 
chromatography were dried and hydrolyzed by gas phase HCl for 20 h at 110oC. 
Following hydrolysis, the samples were dried, suspended in 0.4M borate (pH 10.2) and 
derivatized. Primary amino acids were derivatized with orthophthaladehyde and 
secondary amino acids were derivatized with 9-fluorenylmethoxycarbonyl.  Derivatives 
were separated by reverse phase HPLC and detected by UV absorbance.  Quantitation 





Figure 6.1. Dialysis of caprine serum.  
Control mice were administered 0.1 ml (~5 * 103 CFU)of S. typhimurium i.p. on day 0 
(+), while treated mice received both S. typhimurium on day 0 and a 0.25 ml 
subcutaneous injection of 5 mg 6-8 kDa MWCO effluent ( ) or 1 kDa MWCO effluent 
( ). Each data point represents the average daily mortality (n = 6) with its associated 
standard experimental error per cage of 5 mice. 
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Figure 6.2. Heat denaturation study.  
Control mice were administered 0.1 ml (~5 x 103 CFU)of S. typhimurium i.p. on day 0 
(+), while treated mice received both S. typhimurium on day 0 and a 0.25 ml 
subcutaneous injection of 5 mg 6-8 MWCO dialysis effluent ( ) or 5 mg effluent 
incubated for 30 min at 85oC ( ) or 15 min at 100oC ( ). Each data point represents 
the average daily mortality (n = 6) with its associated standard experimental error per 
cage of 5 mice. 
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Figure 6.3. Protease denaturation study. 
Control mice were administered 0.1 ml (~5 x 103 CFU)of S. typhimurium i.p. on day 0 
(+), while treated mice received both S. typhimurium on day 0 and a 0.25 ml 
subcutaneous injection of 5 mg 6-8 MWCO dialysis effluent ( ) or effluent exposed to 
bromelain and proteinase K ( ).  Positive control mice received only the 
bromelain/proteinase K cocktail ( ). Each data point represents the average daily 
mortality (n = 6) with its associated standard experimental error per cage of 5 mice. 
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Figure 6.4. Size exclusion chromatography of caprine serum and fractionations.  
Twenty l aliquots were applied to a Superdex 200 HR 10/30 size exclusion column 
(Pharmacia LKB Biotechnology) equilibrated in 10 mM sodium phosphate (pH 7.1) and 
150 mM NaCl. The column was calibrated with thyroglobulin (670 kDa), IgG (150 
kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and Vitamin B12 (1.35 kDa). The 
operating system used was a Hewlett Packard 1100 HPLC operated at a flow rate of 1 
ml/min and set to detect at 280 nm.  Samples run were: a. caprine serum; b. 6-8 kDa 
MWCO dialysis effluent (10 mg/ml); and c. TPI (10 mg/ml). 
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Figure 6.5. Centriprep effluent vs. retentate. 
Ultrafiltration was conducted on reconstituted 6-8 MWCO dialysis effluent (10 mg/ml) 
with an Amicon Centriprep YM-10 ultrafiltration device and the Centriprep retentate and 
effluent were collected. Control mice were administered 0.1 ml (~5 x 103 CFU)of S. 
typhimurium i.p. on day 0 (+), while treated mice received both S. typhimurium on day 0 
and a 0.25 ml subcutaneous injection of:  5 mg 6-8 kDa MWCO dialysis effluent ( ), 
Centriprep retentate ( ), or Centriprep effluent ( ). Each data point represents the 
average daily mortality (n = 6) with its associated standard experimental error per cage of 
5 mice. 
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Figure 6.6. SDS gel electrophoretogram of dialysis effluent and TPI.  
Dialysis effluent from 6-8 kDa MWCO dialysis tubing and TPI were analyzed on a 15% 
acrylamide SDS electrophoresis gel and visualized with silver stain.  Samples loaded 
were as follows: Lane A.  10 l BioRad low MW standards (MW in kDa); Lane B. 70 
g dialysis effluent; and Lane C. 70 g TPI. 
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Figure 6.7. Analytical size exclusion chromatography of TPI.  
Twenty-five l TPI (10 mg/ml) was applied to an analytical TSK G2000 SWXL size 
exclusion column equilibrated with 200mM potassium phosphate (pH 6.8) containing 
15mM NaCl.  The system was operated at 0.5 ml/min, the eluate was monitored at 
214nm, and 0.5 ml fractions were collected. 
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Figure 6.8. Bioactivity of analytical size exclusion fractions.  
Control mice were administered 0.1 ml (~5 * 103 CFU)of S. typhimurium i.p. on day 0 
(+), while treated mice received both S. typhimurium on day 0 and proteinaceous 
material obtained from either fraction 25 (352 ng, ), 27 (896 ng, ), or 29 
(1,412 ng, ). Each data point represents the average daily mortality (n = 5) with its 
associated standard experimental error per cage of 5 mice. 
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Figure 6.9. C-18 reverse phase chromatography of TPI.  
Reverse phase HPLC was performed with a C-18 HPLC column (Alltech Absorbosphere 
C-18 5U, 150 mm x 4.6 mm) equilibrated in 0.1% aqueous TFA (trifluoroacetic acid). 
The column (attached to a Waters 600 E HPLC) was washed with this buffer for 10 min 
(1 ml/min) and bound material eluted by establishing a binary gradient which linearly 
increased the secondary buffer (80% acetonitrile, 0.1% aqueous TFA) to 100% over a 20 
min period. A 100 l aliquot of TPI in 0.1% TFA was applied to the column.  Sample 
elution was monitored at 220 nm with an Agilent 1100 Series diode array detector, and 
peak fractions were spectrophotometrically scanned from 200-400nm. 
CHAPTER VII 
CONCLUSION 
Controlled studies demonstrated that CSF-I, material fractionated from caprine 
serum, appeared to possess an immunomodulatory compound (Hamm et al., 2002). 
Caprine serum was further fractionated into three peptidic components -Caprine serum 
fraction - immunomodulator 2 or CSF-I2.  CSF-I2 does not possess antibacterial 
capabilities (as typically characteristic of a cationic peptide or defensin), does not 
contain a level of endotoxin sufficient to promote a pyrogenic response, and its 
functional ability to improve animal survival after an infectious challenge does not reside 
with molecular weight components greater than 10 kDa, effectively excluding the 
immunoglobins, albumin, cytokines, and collectins. Benefit appears to derive from 
proteinaceous components in light of the observation that all benefit is lost after 
proteolytic digestion with bromelain and proteinase K or incubation at 85oC, procedures 
known to denature protein. 
CSF-I2 was able to significantly reduce the mortality observed in chickens (from 
80% to 13%) infected with Pasteurella multocida (Willeford et al., 2000), in mice (from 
83% to 13.3%) infected with Salmonella typhimurium, and in canines (from 50% to 
9.8%) diagnosed with parvovirus.  CSF-I2 may effectively combat pathogenesis when 
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used as either an adjunct with conventional therapy (e.g., antibiotics) or when provided 
as the primary medicant.  CSF-I2 may well prove to provide prophylactic and therapeutic 
health benefits to humans. 
The reduction in mortality realized by pretreatment with CSF-I2 may be due to an 
enhanced clearance of Salmonella in the peritoneal cavity, thereby retarding bacterial 
dissemination and inflammation.  A reduction in inflammation was noted to occur in 
chickens infected with Pasteurella multocida as evidenced by CSF-I2 treated chickens 
expressing lower heterophil counts and increased CD4 counts.  Our studies also showed 
that a caprine serum factor reduced microbial proliferation in splenic tissue. 
While CSF-I2 does not appear to work through directly stimulating macrophages, 
it remains possible that CSF-I2 primes macrophages for augmented production of 
pro-inflammatory cytokines, e.g., in response to S. typhimurium. IFN-  and IFN- /
have been shown to control the growth of intracellular pathogens by inducing 
macrophage production of and subsequent response to interferons (Rothfuchs et al., 
2001). This action would effectively limit the replication of Salmonella at the early stage 
of infection and may allow neutrophils and NK cells to more adequately restrict the 
systemic spread of S. typhimurium and prolong the survival of mice challenged with a 
potentially lethal dose. 
It has not been determined whether functional immunomodulation rests with one 
or more of the peptides isolated, although one peptide appeared to be active.  Three 
factors limited our ability to attack this question successfully, the lack of a sensitive 
bioassay, the limited abundance of the peptide factor, and the probable denaturation of 
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the peptide(s) of interest upon purification.  It may be possible to obtain greater amounts 
of the bioactive peptide(s) by using a preparative size exclusion column (e.g., BioGel 
P2). Upon confirming the presence of bioactivity, it may be possible for sequencing to 
be performed on the peptides of interest, and then through de novo synthesis acquire 
enough purified material to verify bioactivity through an established animal model. 
Ultimately, it will be essential to elucidate the factor s sequence. 
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